Validação de um novo oligossacárido do leite humano para uso em fórmula infantil utilizando tecnologias gastrointestinais in vitro by Almeida, João Pedro Leão Araújo de
 
 
 
 
JOÃO PEDRO 
LEÃO ARAÚJO 
DE ALMEIDA 
VALIDAÇÃO DE UM NOVO OLIGOSSACÁRIDO DO 
LEITE HUMANO PARA USO EM FÓRMULA 
INFANTIL UTILIZANDO TECNOLOGIAS 
GASTROINTESTINAIS IN VITRO 
Universidade de Aveiro 
Ano 2016 
Departamento de Química 
  
 
 
 
JOÃO PEDRO 
LEÃO ARAÚJO 
DE ALMEIDA 
VALIDAÇÃO DE UM NOVO OLIGOSSACÁRIDO DO 
LEITE HUMANO PARA USO EM FÓRMULA 
INFANTIL UTILIZANDO TECNOLOGIAS 
GASTROINTESTINAIS IN VITRO 
Dissertação apresentada à Universidade de Aveiro para cumprimento dos 
requisitos necessários à obtenção do grau de Mestre em Biotecnologia, 
realizada sob a orientação científica da Doutora Sílvia Maria da Rocha 
Simões Carriço, Professora Auxiliar do Departamento de Química da 
Universidade de Aveiro, e do Doutor Pieter van den Abbeele e Beatriz 
Guimarães da empresa ProDigest, Gante, Bélgica. 
VALIDATION OF A NOVEL HUMAN MILK 
OLIGOSACCHARIDE FOR USE IN INFANT 
FORMULA USING GASTROINTESTINAL IN VITRO 
TECHNOLOGIES 
 
Universidade de Aveiro 
Ano 2016 
Departamento de Química 
  
 
 
 
 
 
 
o júri 
 
a presidente 
 
 
Prof.ª Dr.ª Ivonne Delgadillo Giraldo 
professora associada com agregação no Departamento de Química da Universidade de Aveiro 
 
Prof.ª Dr.ª Sílvia Maria da Rocha Simões Carriço (Orientadora) 
professora auxiliar no Departamento de Química da Universidade de Aveiro 
 
Prof.ª Dr.ª Marcela Alves Segundo (Arguente) 
professora auxiliar no Departamento de Química da Faculdade de Farmácia da Universidade do 
Porto  
  
 
  
 
 
palavras-chave 
 
 
 
resumo 
 
aparelho digestivo, cólon, microbiota intestinal, bebés; formulação; prebiótico, 
oligossacárido do leite humano, in vitro; simulator of the human intestinal microbial 
ecosystem (SHIME), ácidos gordos de cadeia curta, amónio, lactato, DGGE, qPCR, B. 
longum subsp. infantis. 
O corpo humano abriga uma comunidade microbiana da qual, parte vive no aparelho 
digestivo. O cólon é a região com a comunidade bacteriana mais densa, denominada 
microbiota intestinal. O seu desenvolvimento em bebés pode ser influenciado por um 
número de fatores, tal como o ambiente intrauterino, tipo de parto e/ou o modo de 
alimentação. No que diz respeito ao modo de alimentação, o leite materno tem um papel 
importante na colonização intestinal de bebés através do fornecimento de uma variedade 
de oligossacáridos. Para bebés que não possam ser amamentados, uma formulação 
infantil é necessária como substituta e, portanto, deve satisfazer as necessidades 
nutritivas dos recém-nascidos. 
A manipulação da microbiota intestinal, recorrendo à adição de probióticos e/ou 
prebióticos à dieta, tem-se tornado uma prática recorrente. Assim, este estudo teve como 
objetivo testar um novo oligossacárido do leite humano (NMO), via experiências 
gastrointestinais in vitro, a fim de proporcionar a melhor formulação possível para 
substituição do leite humano. 
Inicialmente, uma experiência de pré-triagem foi realizada para obter informações 
sobre as potenciais diferenças inter-individuais entre bebés, em resposta à administração 
de NMO. No global, 7 dos 10 dadores responderam intensamente ao tratamento com 
NMO, o que resultou numa acidificação do meio. Um efeito bifidogénico foi também 
observado, com a degradação de NMO ocorrendo através de diferentes cenários de 
resposta. A escolha do dador 10 foi fundamentada tendo em conta a sua elevada taxa de 
fermentação e consequente produção de acetato, mas principalmente devido a um intenso 
efeito bifidogénico, mais especificamente, a um estímulo característico da B. longum 
subsp. infantis, após administração de NMO. 
De seguida, um baby M-SHIME® com 5 unidades foi realizado utilizando amostras 
fecais de um único doador (bebé 10) como inóculo, tornando esta segunda parte do 
projeto ainda exploratória. Diferentes doses de um "golden standard" (GS) e NMO 
foram testados. O consumo base-ácido, as concentrações de ácidos gordos de cadeia 
curta (AGCCs), lactato e amónio e a composição da microbiota foram analisados. 
Durante o período de tratamento, 3.2 g/L de GS, NMO, ou combinações destes, foram 
adicionados aos reatores, resultando no aumento dos níveis de consumo de base-ácido e 
de AGCCs relacionados com a saúde. Um pico no lactato foi observado para as misturas 
e diminuições dos níveis de marcadores proteolíticos foram também observados. No que 
diz respeito a mudanças na composição de Bifidobacterium, GS provocou um estímulo 
de B. longum, enquanto NMO aumentou a abundância de B. longum subsp. infantis, com 
um efeito dose-resposta claro em ambas as situações. 
No decorrer do tempo, a administração NMO causou também um aumento dos níveis 
de Enterobacteriaceae com relação dose-resposta. Das enterobactérias podem também 
fazer parte alguns agentes patogénicos e, sendo assim, a dosagem de NMO seria 
recomendada. A dose ótima pode, por conseguinte, ser a dose para a qual existe ainda 
uma forte estimulação de B. longum subsp. infantis e AGCCs relacionados com a saúde, 
embora não resultando numa grande expansão de enterobactérias, como, por exemplo, 
75% / 25% ou 50% / 50% (GS / NMO). 
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human gastrointestinal tract, colon, gut microbiota, Infants, Formula, prebiotic, human 
milk oligosaccharide, in vitro, simulator of the human intestinal microbial ecosystem 
(SHIME), short chain fatty acids, ammonium, lactate, DGGE, qPCR, B. longum subsp. 
infantis. 
The human body harbours a microbial community, part of which lives in the 
gastrointestinal tract. The colon is the region with the densest bacterial community, 
called gut microbiota. Its development in infants may be influenced by a number of 
factors, like intra-uterine environment, delivery mode and/or the feeding mode. 
Regarding the feeding mode, human breast milk plays an important role in early gut 
colonization of infants. It does so by providing a variety of human milk oligosaccharides. 
For infants who cannot be breastfed, infant formula is required as a substitute and so, 
must satisfy the nutritional requirements of infants. 
Since modulation of gut microbiota resorting to the addition of probiotics and/or 
prebiotics to the diet is increasingly becoming a recurrent practice, in order to provide 
infants that do not receive breast-feeding with the best possible alternative formula 
feeding, this study aimed to test a new human milk oligosaccharide (NMO) via 
gastrointestinal in vitro experiments. 
Firstly, a pre-screening experiment was performed to gain information on the 
potential inter-individual differences among babies in response to NMO administration. 
Overall, 7 out of the 10 donors responded strongly to the NMO treatment resulting in an 
acidification of the medium. A bifidogenic effect was also noted, with NMO degradation 
being found to occur via several different response scenarios. The choice of donor 10 
was substantiated based on the strong overall fermentation and corresponding acetate 
production, but mainly due to a strong bifidogenic effect and thus, most interestingly, a 
specific stimulation of B. longum subsp. infantis upon NMO administration. 
Afterwards, a 5 units’ baby M-SHIME® experiment was performed using faecal 
sample from a single donor (donor 10) as the inoculum, making this second part of the 
research still exploratory. Different doses of a “golden standard” (GS) and NMO were 
tested.  Base-acid consumption, short chain fatty acids (SCFAs), lactate, ammonium 
concentrations and microbiota composition were analysed. For the treatment period, 3.2 
g/L of GS, NMO or combinations of thereof were supplemented to the vessels resulting 
in increased base-acid consumption and health-related SCFAs levels. A peak in lactate 
was observed for the mixtures and minor decreases were also observed on proteolytic 
markers. With respect to changes in Bifidobacterium composition, it followed that GS 
stimulated B. longum, while NMO increased the abundance of B. longum subsp. infantis 
with a clear dose-response effect in both situations.  
Over time, NMO administration caused an increase of Enterobacteria levels in a dose-
related way. Given the fact that Enterobacteria also contain opportunistic pathogens, 
dosing would be recommended. The optimal NMO dose might therefore be the dose at 
which there is still a strong stimulation of B. longum ssp. infantis, and health-related 
SCFAs, although not resulting in a major expansion of Enterobacteria, like for example 
75% / 25% or 50% / 50% (GS / NMO). 
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 1 
 
I. INTRODUCTION 
 
One of the most crucial shaping steps of human history was the discovery of bacteria, 
back in 1675 by a Dutch tradesman and scientist, named Antonievan Leeuwenhoek, the 
“Father of Microbiology”. It still lasted until the 1800’s, when for the first time, 
microorganisms were shown to cause disease. This was the trigger for a major scientific 
revolution leading to a better understanding, prevention and cure of microbial diseases 
resulting, for example, in improved hygiene, vaccinations and antibiotics (Dethlefsen et al., 
2007).  
However, most interactions between humans and microorganisms do not result in 
disease. 
The interactions between host and non-pathogenic microorganisms are even essential 
to many aspects of normal mammalian physiology, therefore greatly influencing the being’s 
health (Dethlefsen et al., 2007).  
With this in mind, the human body harbours a microbial community which has been 
estimated to collectively consist of ten times more cells as compared to the number of human 
cells in a healthy adult (Qin et al., 2010). This microbial community, also called the human 
microbiota, includes archaea, fungi, viruses, protozoa and mainly, bacteria (Cénit et al., 
2014). Due to the high volume, microorganisms are present in various body habitats such as 
in our skin surface. The gastrointestinal tract (GIT) is the most colonized  part of the human 
body (Bianchi et al., 2014), with the colon harbouring a very dense and metabolically active 
microbial community called, the gut microbiota. 
In contrast, the stomach is the region having the lowest bacterial density (101-103 
cfu/mL), as schematized in Figure 1, 
since most bacteria are  hindered by 
gastric secretions such as acid, bile or 
pancreatic juice (O’Hara and Shanahan, 
2006). The gut microbiota rises up to an 
estimated 1011–1012 bacteria per gram of 
colonic content, contributing to 60% of 
faecal mass (O’Hara and Shanahan, 
2006). 
Figure 1 – Bacterial densities corresponding to different 
anatomic regions of the GIT (edited from O’Hara and 
Shanahan, 2006) 
Oesophagus 
104 – 106 cfu/ml 
Duodenum 
101 – 103 cfu/ml 
Colon 
1011 – 1012 cfu/ml 
Stomach 
101 – 103 cfu/ml 
Ileum 
104 – 107 cfu/ml 
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1. Gut Microbiota 
 
1.1 Characterization 
During a long term study, the composition of an individual’s gut microbiota was 
shown to remain fairly stable throughout an adult’s life (Martín et al., 2014). Aerobic and, 
predominately, anaerobic bacteria are present, with Firmicutes, Bacteroidetes, 
Actinobacteria (which includes the genus Bifidobacterium), Proteobacteria and 
Verrucomicrobia being the most dominating phyla (Cammarota et al., 2014).  
Nevertheless, the bacterial population is continuously subjected to internal and 
external parameters that will affect the final structure and functions of the gut microbiota, 
making it unique. In order to fulfil specific niches, also other phyla colonize this microbiota 
including, Chlamydiae, Cyanobacteria, Deferribacteres, Deinococcus, Thermus, 
Fusobacteria or/and Spirochaetes (Dethlefsen et al., 2007).  Altogether, about 1000 bacterial 
species reside in the human gut alongside with other microbial species (Cammarota et al., 
2015). 
The internal parameters that affect the gut’s microbiota composition are residence 
time, pH, exposure to oxygen, nutrient availability, host secretions, and the presence and 
activity of immune cells and mucosal surfaces (Louis et al., 2014). Particularly interesting is 
the last parameter, as only few specific bacterial species are capable of colonizing mucus 
surfaces, resulting in a unique bacterial composition in the mucus layer versus the lumen. 
As the microbes in the mucus layer reside very close to the epithelial lining, they have a high 
potential to affect human health. Important mucosal microbes include butyrate-producing 
species (Van den Abbeele et al., 2013) and mucin-degrader bacterium, Akkermansia 
mucinphila (Sommer and Bäckhed, 2013).  On the other hand, external parameters comprise 
environmental factors and the host’s lifestyle, diet and age (O’Hara and Shanahan, 2006).  
Further, in a comparative study of the gut microbiome of adults, the authors showed 
strong positive correlation between the microbial composition and the genetic relation of 
their hosts. The authors suggested that the host genotype also has a significant effect on the 
bacterial diversity, even prevailing over environmental factors (Erwin G. Zoetendal, 2001).  
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1.2 Function 
The human gut microbiota plays a key role in numerous metabolic, physiological, 
nutritional and immunological processes, including fermentation of complex diet-derived 
host-indigestible substrates (mainly carbohydrates and proteins), synthesis of vitamins and 
maturation of immune cells for the normal development of host immune functions (Clarke 
et al., 2014; Marques et al., 2010). In addition, the indigenous gut microbiota can also 
prevent invasion of pathogens by competing for the colonization of the specific niches in the 
gut microbiome, thus preventing them from taking roots in the bowel (Cammarota et al., 
2015). 
One of the most important metabolites of gut microbes are short-chain fatty acids 
(SCFAs) (Pryde et al., 2002). The main SCFAs are acetic, propionic and butyric acids, which 
occur normally in 60:20:20 molar ratios. By absorbing and metabolizing SCFAs, the host is 
able to salvage energy (Clarke et al., 2014). Other possible effects of SCFAs on the human 
body is that they can affect epithelial cell transport and metabolism, epithelial cell growth 
and differentiation or hepatic control of lipid and carbohydrates (Clarke et al., 2014).  
Butyrate is the SCFA which has been receiving most attention because it has 
important physiological functions in eukaryotic cells (e.g. histone acetylation) and, most 
importantly, because butyrate has anti-inflammatory and anti-carcinogenic effects on the 
human host (Flint et al., 2012; Mischke and Plosch, 2013). Butyrate is mainly produced by 
oxygen-sensitive anaerobes belonging to the Clostridium clusters IV and XIVa (also known 
as the Clostridium leptum and Clostridium coccoides groups, respectively). As schematized 
in Figure 2, two chemical pathways are responsible for producing butyrate: the butyryl-
CoA/acetate-CoA transferase pathway, the most predominant, and the butyrate kinase 
pathway (Pryde et al., 2002; Vital et al., 2013).  
Propionate is produced by Bacteroides species and members of the Clostridium 
cluster IX group, via the succinate and acrylate pathways, respectively (Fig. 2) (Van den 
Abbeele et al., 2011). Propionate is most known for having influence on lowering cholesterol 
and improving glucose homeostasis on the human host (Flint et al., 2012). 
Regarding acetate, although it may be produced almost by any bacterium, its main 
producers are lactic acid bacteria, particularly Bifidobacteria and Lactobacilli, which are 
also able to produce lactate (lactate-producing bacteria). These bacteria are unable to 
produce either propionate or butyrate, however they are linked to their increase. By a process 
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called cross-feeding, acetate and lactate produced by lactic acid bacteria may be converted 
into butyrate and propionate, respectively, by lactate-utilizing microorganisms (Fig. 2). 
Other SCFAs, including valerate, isobutyrate, formate or isovalerate can also be 
produced but in lower quantities, alongside with other end products such as ethanol, 
methanol and hydrogen sulphide (Louis et al., 2014) .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collectively, the gut microbiota exerts a metabolic activity that can be compared to 
a virtual organ within an organ (O’Hara and Shanahan, 2006). Therefore, perturbations in 
the gut microbial ecology (dysbiosis) may affect host resilience, gut permeability and alter 
the susceptibility to metabolic disorders resulting in adverse consequences for host health 
(Cani et al., 2008). Those consequences usually consist of pathological intestinal conditions 
such as chronic inflammatory diseases particularly, inflammatory bowel diseases, 
encompassing ulcerative colitis and Crohn’s disease (Park et al., 2005). Such diseases can 
indeed be associated with specific alterations in the composition of the microbiota. As an 
example, in Crohn’s disease patients, an outgrowth of the following bacterial taxa has been 
observed: species belonging to the Bacteroides genus, the Enterobacteriales order and to the 
Enterobacteriaceae family including pathogens belonging to the Salmonella, Shigella and 
Figure 2 – Schematic representation of main pathways for carbohydrate fermentation and production of the 
three main SCFAs (acetate, propionate and butyrate) in the colon (edited from Pryde et al., 2002).                                                              
(1) phosphotransbutyrylase/butyrate kinase; (2) Butyryl-CoA/acetate-CoA transferase; (3) Acrylate pathway; (4) 
Succinate pathway. 
4 3 
1 
2 
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Escherichia genera (Cammarota et al., 2015). Further, in IBD patients, the changes in 
bacterial abundances have been linked to an alteration of metabolic functions of gut 
microbiota, such as a decrease in the metabolism of SCFAs and biosynthesis of amino acids, 
as well as an increase in auxotrophy, oxidative stress and secretion of toxins (Cammarota et 
al., 2015). 
In addition to its local action, the 
action range of the gut microbiota goes 
even beyond the GIT. As demonstrated 
in Figure 3, clear links have been 
established between the composition of 
our intestinal microbiota, its functional 
endocrine interactions and the 
development of obesity, cardiovascular 
disorders and metabolic syndromes, as 
well as stress-related psychiatric 
disorders (Clarke et al., 2014). 
Especially the bidirectional communication system between the gut and the brain – the brain-
gut axis – which is considered vital for maintaining homeostasis, is gaining a lot of interest 
by the scientific community (Zhou and Foster, 2015). 
In conclusion, the gut microbiota can no longer be considered a bystander in health 
and disease (Clarke et al., 2014). 
 
1.3 Gut Microbiota Manipulation 
The concept of modulating the human gut microbiota via the diet is not new. Three 
different approaches stood out in recent years: the addition of probiotics in foods, the 
selective stimulation of beneficial microorganisms indigenous to the gut with prebiotics, and 
a combination of both approaches (synbiotics) (Sivieri et al., 2014).  
 
i. Probiotics 
The term “probiotic” is a blend of Latin (pro=for, in favour of) and Greek (bios=life) 
(Ventura et al., 2015) and is officially defined as “live microorganisms which, when 
administered in adequate amounts, confer a health benefit on the host” (FAO/WHO, 2002). 
Figure 3 – Implications of endocrine output of the gut 
microbiota in health and disease (edited from Clarke et al., 
2014). 
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Several key regulations were outlined by the FAO/WHO Working Group for the Evaluation 
of Probiotics in Food, specifically: 
a. A probiotic must be alive when administered (although preparations of dead 
cells and cell components may also exert health-promoting physiological 
effects – postbiotics); 
b. Probiotics must be delivered at an effective dose; 
c. Probiotics must be taxonomically defined microbes or combination of 
microbes; 
d. Probiotic must be safe for its intended use; 
e. Probiotics must undergo controlled evaluation to document health benefits in 
the target host (Venema and do Carmo, 2015; Ventura et al., 2015).  
Lactic acid bacteria have been the mostly investigated bacteria for use as potential 
probiotic (Bezirtzoglou and Stavropoulou, 2011). They can already be found in many 
products, such as dairy products. In regard to the mode of action of these or any other 
probiotics, it still is largely unclear what molecular effector determines whether one strain is 
active whereas another is not (Angelakis et al., 2013). However, possible mechanisms of 
action include that probiotics can prevent the colonization of pathogenic bacteria by 
decreasing intestinal pH, releasing antimicrobials (e.g. bacteriocins) or by competing for 
growth on substrates or for adhesion sites at the gut wall (Angelakis et al., 2013).  
The prime example of lactic acid bacteria on probiotics is Bifidobacteria. Belonging 
to the genus Bifidobacterium (Actinobateria phylum) and first isolated in 1899 by Henri 
Tisser, they encompass 48 species, including four taxa (longum, pseudolongum, animalis 
and thermacidophilum) that are further divided into subspecies, all of which share more than 
93% identity in their 16S rRNA sequences (Ventura et al., 2015). 
Bifidobacterium is vastly distributed among living organisms that provide their 
offspring with parental care such as mammals, birds and social insects. This means that an 
important reason of their wide distribution may be due to direct transmission from parent to 
offspring (Turroni et al., 2011), which may also imply an important role of these bacteria in 
their hosts. In fact, in case of humans infants, colonization at an early stage by Bifidobacteria 
is known to be an important factor for health (Favier et al., 2003). 
Several health benefits are attributed to the presence of Bifidobacteria in the human 
gut, including reduction of cholesterol, diarrhoea and constipation, lessening effects of 
 7 
 
lactose intolerance, prevention of colon cancer, protection against infectious diseases, 
modulation of mucosal barrier function, amino acid and vitamin production, SCFAs 
production, and more (Hoover, 2014; Kondepudi et al., 2012; Leahy et al., 2005; Ventura et 
al., 2015). 
Although the molecular basis of the mechanisms occurring between the intestinal 
host epithelium and Bifidobacteria is still unclear, all sequenced Bifidobacteria appear to 
encode an extracellular polysaccharides, cell envelope-associated structures, which may be 
crucial in bacterial adherence to host cells, as well as resistance to host secretions (Turroni 
et al., 2011). Bifidobacteria were also shown to present some fimbriae-like structures whose 
role has not yet been fully determined. Nonetheless, looking at other human GIT inhabitants 
which contain similar structures, one may expect that they also contribute to bacterial 
adherence and colonization on host cells surfaces  (Turroni et al., 2011). 
Recently, the EFSA (European Food Safety Authority) ruled out the possibility of 
using the word “probiotic” in any product. They claim that many products said to be 
probiotics contained only Bifidobacteria (and/or Lactobacilli) and had no substantial effect. 
 
ii. Prebiotics 
A different approach that has attracted interest is the use of prebiotics. The most 
recent definition for prebiotics given by the International Scientific Association of Probiotics 
and Prebiotics (ISAPP) is: “a selectively fermented ingredient that results in specific changes 
in the composition and/or activity of the gastrointestinal microbiota, thus conferring 
benefit(s) upon host health” (Śliżewska et al., 2012). The potential benefits resulting from 
the intake of prebiotics are schematized in Figure 4. 
Prebiotics normally consist of carbohydrates (di, oligo and polysaccharides) that are 
non-digestible for the (human) host (Patel and Goyal, 2012). Prebiotics have to fulfil a few 
basic requirements. Firstly, they have to resist to gastric acids, host enzymes and 
gastrointestinal absorption. Further, they should be fermented by intestinal microbes and 
stimulate the growth and/or activity of specific intestinal bacteria (Roberfroid et al., 2010). 
Some examples of well-established prebiotics are summarized in Table 1. 
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Prebiotic substrates offer several advantages over probiotic bacteria, including: 
 Long shelf life; 
 Heat and pH stable in a wide range of food products; 
 Prebiotics enhance food taste and texture  
 Prebiotics target specific strains that are already present in the intestinal tract of an 
individual, avoiding issues of probiotic that need to compete with intestinal bacteria 
that are well established in their niche (Śliżewska et al., 2012). 
For these and other reasons, the prebiotic functional food market has grown into a 
multi-million Euro industry, with the prebiotic market accounting for an estimated €10.58 
billion in 2012. By 2019, it is expected to grow to €15.03 billion (Transparency Market 
Research, 2014). 
Nevertheless, until it can be officially released to the market, a prebiotic substrate 
must go through several stages, described in Figure 5. The goal of this process is to assess 
the safety of the product in the host and to confirm its health effects.  
 
 
 
 
 
PREBIOTIC
S 
Soften stools 
Increased beneficial bacteria 
Positive effect on 
local GIT 
immunity 
Increased 
SCFA 
production 
Decreased 
pathogenic 
bacteria 
Lower pH 
Positive effect on 
general immunity 
Increased gut 
maturation 
Improved nutrient 
absorption 
Figure 4 – Potential beneficial effects of prebiotics on infant health (edited from Donovan et al., 2009). 
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Table 1 - Most common and used prebiotics and their respective chemical structure and method of manufacture 
(edited from Śliżewska et al., 2012). 
 CHEMICAL  
STRUCTURE 
METHOD OF 
MANUFACTURE 
Disaccharides   
Lactulose β(1-4)-Fructans 
Enzymatic treatment of 
lactose 
Polysaccharides   
Inulin β(2-1)-Fructans 
Extraction from chicory root 
and Agave tequilana 
Dextrin 
Mixture of 
oligosaccharides 
containing glucose 
Chemical modification of 
starch 
Oligosaccharides   
Fructooligosaccharides (FOS) β(2-1)-Fructans 
Transfructosylation from 
sucrose or hydrolysis of 
chicory inulin 
Galactooligosaccharides (GOS) 
Galactose oligomers and 
some glucose/ lactose/ 
galactose units 
Produced from lactose by β-
galactosidase 
Soya-oligosaccharides 
Mixture of raffinose and 
stachyose 
Extracted from soya bean 
whey 
Xylooligosaccharides (XOS) 
 
β(1–4)-Linked xylose 
Enzymatic hydrolysis of 
xylan. Enzyme treatments of 
native lignocellulosic 
materials. Hydrolytic 
degradation of xylan 
Isomaltooligosaccharides (IMO) 
α(1–4)-glucose and 
branched α(1–6)- glucose 
Microbial or enzymatic 
transgalactosylation of 
maltose. Enzymatic synthesis 
from sucrose 
Independent test 
Characteristics of the substance (purity, chemical composition, source…) 
Characteristics of the functionality, in vitro tests 
Formulation of the product 
Safety assessment (animal or human trials) 
Efficiency confirmation (randomized controlled tests on human) 
PREBIOTIC 
Figure 5 – Main guidelines to the assessment and proof of the action of prebiotics (edited from Śliżewska 
et al., 2012). 
 10 
 
2. Early Life Microbiota 
 
The assembly of a complex community of microorganisms in the gut is a nice 
example of how beneficial interaction is established between a developing microbial 
ecosystem and its host (Ventura et al., 2015). Formation of such a human-microorganisms 
symbiosis during early life is a complex and important biological process and should not be 
regarded as a succession of steps, but rather as a complex process influenced by microbial 
and host interactions and by external and internal factors (Fanaro et al., 2007).  
Early colonizers of the gut typically include facultative anaerobes (or aerotolerants) 
belonging to Proteobacteria phyla, like Enterobacteriaceae and Streptococcus, whose 
number attains 109 CFU/g faeces (Bezirtzoglou, 1997; Fanaro et al., 2007; Kirmiz and Mills, 
2016). From then on, the infant’s gut microbiome will undergo rapid maturation over the 
first year of age, moving toward an adult-like microbiota within the first 3 years after birth 
(Matamoros et al., 2013).  
The gradual consumption of oxygen in the intestine by aerobic microorganisms 
decreases the oxidation-reduction potential, thus providing optimal conditions for the 
settlement of a more diversified microbiota (Lopetuso et al., 2013). After the colonisation of 
facultative anaerobes, obligate anaerobic bacteria expand, changing the general structure of 
the gut microbiota. This new complex microbiota dominated by obligate anaerobes, mainly 
Bifidobacteria, promotes the establishment of butyrate producers by cross-feeding and  
provides a barrier against the proliferation of new non-beneficial bacterial strains, a 
phenomenon termed “colonization resistance” (Adlerberth and Wold, 2009). 
It should be noted though, that such shifts in microbial composition may represent 
an outgrowth of specific groups of bacteria that were already present, albeit at low level. 
That is, for instance, the case for Bifidobacteria, whose abundance increases from 3.5-10% 
in the infant microbiota to about 50–70% during the first month age after birth (Nylund et 
al., 2014). At 3 months age, Bifidobacteria compose even 90% of the microbiota (Nylund et 
al., 2014). After the weaning and introduction of solid foods, Bifidobacteria gradually 
decrease in abundance reaching 60% at 4 months of age, 25% at 6 months and 10% at 2 
years. At that time, microbial signatures start stabilizing and resembling the ‘adult state’ 
(Sommer and Bäckhed, 2013) 
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Even though the stabilization to an adult-like composition is reported to take place 
on this short notice, a few studies still suggest that it lasts throughout the entire childhood 
and adolescence, since major physiological changes are taking place in the human body. In 
a recent study, Hollister et al. (2015) compared the gut microbiotas of healthy adults versus 
healthy pre-adolescent children (age 7-12 years). They showed that both composition and 
functional potential were significantly different in both age groups, although they both 
harboured similar numbers of taxa and functional genes. Children were enriched in 
Bifidobacterium spp., Faecalibacterium spp. and members of the Lachnospiraceae, while 
adults harboured greater abundances of Bacteroides spp. These findings suggest that gut 
microbial community may undergo a more prolonged development than previously 
suspected. 
As mentioned before, a number of external factors may influence the process of 
microbial colonization in infants. These factors, listed in Table 2, may affect the infant’s 
health, reason for they should always be taken into account. 
 
 
Table 2 – Summary of the factors affecting gut microbiota colonization in infants (edited from Munyaka et al., 2014). 
Factors affecting 
colonization of gut 
microbiota before birth 
Factors affecting colonization 
of gut microbiota at birth 
Factors affecting 
colonization of gut 
microbiota after birth 
-Intra-uterine environment 
-Maternal exposures or 
practices such as stress, 
antibiotic use, smoking 
-Length of gestation period 
(term vs preterm) 
-Mode of delivery (caesarean 
section vs vaginal delivery) 
-The environment at the time of 
delivery  
-Contact with the mother or 
health care staff 
-Breastfeeding vs formula 
feeding 
-Weaning or food 
supplementation 
- Antibiotic exposure 
- Home or family setting 
(rural vs urban) 
- Home structure (contact 
with family members) 
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2.1  Intra-uterine environment 
Vertical transmission of maternal microbiota is the most important contribution to 
the genesis of an individual´s microbiota (Gritz and Bhandari, 2015). However, until now, 
the general idea was that the human foetus was microbiologically sterile before birth and 
that the passage of the infant through the birth canal was the only process responsible for 
colonization of new-borns. Likewise, the presence of microbes in the amniotic fluid and 
placenta was thought to be only associated with preterm deliveries due to maternal 
intrauterine infections (Nylund et al., 2014). Nonetheless, recent studies have shown that 
DNA of non-pathogenic bacteria can be detected in placenta and amniotic fluid samples even 
in normal conditions (Nylund et al., 2014). Hence, because foetuses begin to swallow large 
amounts of amniotic fluid as they become more neurologically mature, we can, therefore, 
affirm that the ingestion of amniotic fluid during pregnancy already exposes the foetus to 
bacteria (Gritz and Bhandari, 2015). In 2001, Aagaard and colleagues confirmed this idea 
after they characterized a placental microbiome profile, finding that this microbial 
community shared some similarities with the human oral microbiota (Aagaard et al., 2014). 
Both were composed of non-pathogenic commensal microbiota from the Firmicutes, 
Tenericutes, Proteobacteria, Bacteroidetes, and Fusobacteria phyla.  
Several reports have also described the microbiota composition from the very first 
faecal specimen produced by infants after birth, the meconium, which consists mainly of 
amniotic fluid but includes also mucus, intestinal epithelial cells and concentrate of 
metabolites such as bile acids and pancreatic secretions (Nylund et al., 2014). Accordingly, 
they concluded that bacteria belonging to the major bacterial phyla in the intestine are 
already detectable which, once again, reinforces the idea that the colonization process of 
human foetus begins well before delivery. 
Despite aforementioned findings, this idea is still not 100% accepted because the 
presence of bacteria in the amniotic fluid could also reflect an undetected infection. The 
presence of bacterial species in the meconium, such as Escherichia coli, E. faecium, and 
Staphylococcus epidermidis, could result from the translocation of the mother’s gut bacteria 
via the bloodstream (Munyaka et al., 2014). 
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2.2 Delivery mode 
Either with intrauterine influence or not, the mode of delivery is another factor that 
can affect the establishment of the infant gut microbiota, as it has been shown that babies 
born by caesarean section (C-section) develop a microbiota different from babies vaginally 
delivered, alongside with inefficient short-term immune responses and a greater long-term 
risk of developing immune diseases (Clarke et al., 2014). This proves that direct transmission 
of the vaginal microbiota provides the baby with an initial set of bacteria, occupying niches 
and reducing the colonization by pathogens as site-specific communities develop. 
Dominguez-Bello et al. (2010) compared the initial microbiota of new-borns 
immediately after birth. As expected, they confirmed that the dominant taxa found in infant 
communities were reflective of delivery mode. Lactobacillus, Prevotella, Atopobium or 
Sneathia spp. were abundant in aggregate samples from vaginally delivered babies, and 
typical skin taxa, including Staphylococcus spp., appeared in samples from C-section infants.  
Most vaginal and skin bacteria do not seem to take hold in the infant gut but, their 
initial presence may differentially affect the colonization capacities of other bacteria 
(Francino, 2014). Indeed, in surveys performed at 3 days and 1 month of age, Penders et al. 
found  that infants born by C-section were much less likely to be colonized by 
Bifidobacterium and Bacteroides at both times. These findings may, in part, explain why 
susceptibility to certain pathogens is often higher in C-section than in vaginally delivered 
infants.  
 
2.3 Feeding mode 
Another strong, and possibly the major one, factor influencing the development of 
the infant intestinal microbiota is the mode of feeding, with studies suggesting differences 
in microbial colonization of breast-fed versus formula-fed infants.  
Breast-feeding is associated with numerous beneficial effects on the new-born 
(Kirmiz and Mills, 2016). Studies have linked breast-feeding with a reduction in the risk of 
asthma, obesity, type 1 and 2 diabetes and necrotizing enterocolitis, among other health 
benefits (Kirmiz and Mills, 2016). One of the explanations given for these wide range of 
benefits is the bacterial content present in breast milk. Collado et al. (2009) confirmed this 
while characterizing the breast milk microbiota of 50 healthy women. Staphylococcus, 
Streptococcus, Bifidobacterium and Lactobacillus were the most predominant groups. 
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Furthermore, genotyping of bacterial isolates from the breast milk of mothers and faecal 
samples of their infants revealed the presence of identical strains, suggesting once again an 
important role of breast milk as a source of early gut colonization in infants. 
Human breast milk is also an important source of human milk oligosaccharides 
(HMOs), the third most abundant component of human breast milk after lactose and lipids 
(Underwood et al., 2015). They are believed to act as selective ‘natural’ prebiotics therefore 
promoting the colonization of the breast-fed infant gut with beneficial microbes as opposed 
to children fed with formula (Munyaka et al., 2014). Bifidobacteria, is the major bacterial 
group able to utilize such milk oligosaccharides (Nylund et al., 2014). Ward et al. was the 
first to prove this by showing that Bifidobacteria, in that case Bifidobacterium infantis ATCC 
15697, could grow to high cell densities in vitro on HMOs as a sole carbon source. In another 
study, De Leoz et al. (2015) examined infant faecal HMOs in relation to faecal bacterial 
population in two healthy infants over the first few weeks of life. By week 13 they observed 
that there was a decrease in faecal HMOs, whereas Bifidobacterium spp. and also 
Bacteroides spp. had increased. 
When comparing the faecal microbiota of breast-fed and formula-fed infants (n=12), 
Bezirtzoglou et al. (2011) found that they differ significantly in both composition and 
diversity using fluorescence in situ hybridization. It was concluded that breast-fed infants 
harbour a faecal microbiota dominated by Bifidobacteria (72.25%), with abundances being 
two times higher as compared to formula-fed infants. Finally, the microbiota of breast-fed 
infants might be more complex than previously thought. This relates to the finding of high 
levels of Ruminococci in breast-fed infants 1 month old (n=39). The authors suggested that 
Ruminococci might have a similar major role as Bifidobacteria, in breast-fed babies (Coppa 
et al., 2011). 
Furthermore, healthy formula-fed infants are colonized by a more diverse population, 
including also bifidobacterial species seen in adults such as B. adolescentis. In contrast, 
healthy breast-fed infants are colonized by a small number of subspecies including B. 
infantis, B. longum, and B. breve and to a lesser extent B. bifidum and B. pseudocatenulatum. 
This is in accordance with the enhanced capacity of HMO consuming B. infantis, which is 
considered the archetypical HMO-utilizing bacterium (D. a Sela et al., 2008). 
As already mentioned, the introduction of solid food causes a new shift in the gut 
microbiota of children evening out the differences between formula and breast-fed babies. 
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Yet, the gut colonization depends on the nature of food received, which can be stratified by 
cultural influences or geographical location. De Filippo et al. (2010) investigated and 
compared human intestinal microbiota from two groups of children characterized by a 
modern western European diet (Italy) and a rural African diet (Burkina Faso), respectively. 
The graphs presented in Figure 6 show meaningful differences between the two 
groups, indicating a significant enrichment in Bacteroidetes and depletion in Firmicutes in 
rural African children. Moreover, a unique abundance of bacteria from the genus Prevotella 
and Xylanibacter, known to contain a set of bacterial genes for cellulose and xylan 
degradation was specifically found in African children, while completely lacking in 
European children. The authors suggested that gut microbiota most probably coevolved with 
the polysaccharide-rich diet of Burkina Faso individuals, allowing them to maximize energy 
intake from fibres. 
 
 
 
 
 
 
 
 
 
 
 
 
  
A B                                                
Figure 6 – Pie charts of median values of 16S rRNA gene surveys showing bacterial genera present in 
faecal samples of children from A) Burkina Faso and B) Italy (edited from De Filippo et al., 2010) 
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3. Supplemented Infant Formula 
 
For infants who cannot be breastfed, infant formula is required as a substitute for 
mother’s milk and, for that reason, infant formula must satisfy the nutritional requirements 
of infants (Koletzko, 2015). However, in contrast to human milk, cow’s milk (usually used 
in infant formula) contains only trace amounts of oligosaccharides and so,  to fulfil this gap, 
oligosaccharides must be provided exogenously, although it is not possible to add 
oligosaccharides structurally identical to HMOs (Donovan et al., 2009). Therefore, 
researchers have been evaluating the feasibility of adding food-grade prebiotic ingredients 
to mimic the functional properties of HMOs in infants’ gut microbiota. 
Regarding safety questions of this specific issue, the accumulated data concluded that 
the use of currently used formula with added prebiotics in healthy infants does not raise 
safety concerns (Braegger et al., 2011). 
Several food-grade oligosaccharides have been evaluated and are currently in use as 
prebiotics in infant formula, mainly GOS and FOS, though inulin and lactulose have already 
been studied. Combinations of these products have also been evaluated. Prebiotic 
oligosaccharides have only been added to infant formulas in Europe within the first decade 
of the 21st century, although 90% of infant formulas in Japan already contain prebiotics 
(Ziegler et al., 2007). 
Many studies have evaluated the effectiveness of individual prebiotics on gut 
microbial composition. In one study, Ben et al. (2008) decided to investigate the effect of 
only 2.4 g of GOS per 1L of formula on intestinal microflora colonization and fermentation 
in formula-fed term infants compared with breast-fed and control formula-fed counterparts. 
Infants were followed up for 3 months and, when not breastfed, some were randomly 
assigned to test formula group and control formula group. At the end of the feeding period 
the results, presented in Table 3, show that even with low levels of GOS, the number of 
intestinal Bifidobacteria (and also Lactobacilli) was significantly increased both in GOS-
supplemented formula-fed infants and in breast-fed infants, compared with those fed with 
the control formula. 
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Table 3 – Levels of intestinal bacteria at the end of a 3 months feeding period as measured in fresh faeces (edited from 
Ben et al., 2008) 
 GOS formula Human milk Control formula 
Bifidobacterium 9.01 ± 1.18 9.25 ± 0.93 8.16 ± 0.99 
Lactobacilli 5.91 ± 1.61 5.45 ± 2.16 4.27 ± 2.02 
(Note: Data are presented as mean ± SD Log10 CFU/g wet faeces. Control formula does not contain added GOS) 
 
 
A more recent work had similar results. The study consisted on randomly assigning 
infants to receive an infant formula until 6 months of age and then the follow-on formula 
until 12 months of age either with GOS supplementation (GOS group) or without (control 
group). As expected, Bifidobacteria increased in infants in the GOS group compared with 
the control group, although, this time no general differences were observed for Lactobacilli 
(Sierra et al., 2015). 
In a different study, the authors decided to analyse the effect caused when feeding 
infants with a formula containing a combination of GOS and FOS in a 9:1 proportion (4 g/L) 
(Holscher et al., 2012). Formula-fed infants were randomized to consume a partially 
hydrolysed formula with or without the prebiotic and compared to a breast-fed infants group. 
In the end, stool of infants consuming the prebiotic clearly had the best results. Figure 7 
shows us that the prebiotic consuming group (PRE) had a higher absolute number and 
proportion of Bifidobacteria than non-consuming prebiotic groups (CON and BF). 
Moreover, the amount of Bifidobacteria on faecal material did not differ significantly 
between breast-fed infants and prebiotic consuming group. 
Figure 7 – A) Absolute abundance (CFU/g) and B) Relative abundance (percentage of total) of faecal 
Bifidobacteria in breast-fed infants and infants consuming prebiotic and control formulas (edited from 
Holscher et al., 2012). BF:breastfed; CON:control infant formula group; PRE:prebiotic infant formula group. 
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In a study aiming to test inulin as prebiotic in an infant formula, formula-fed infants 
(n=56) were enrolled to receive either the prebiotic or placebo (Kapiki et al., 2007). Faecal 
samples were taken at inclusion day and seven days later. Once again, faecal bacterial counts 
showed that the microbiota of supplemented infants were more heavily colonized with 
Bifidobacteria and had fewer potentially pathogenic bacteria (E. coli and Enterococcus) 
compared to infants fed with non-supplemented control formula. 
Moro et al. investigated the effect on bacterial growth caused by the supplementation 
of different dosages of prebiotic, specifically, GOS:FOS (9:1). For that, infants were 
randomized to receive control formula or formula containing either 4 g/L or 8 g/L of 
GOS:FOS. At the end of a 28-day treatment period, the number of Bifidobacteria in the 
stools was significantly higher in both groups fed the supplemented formulas than in the 
stools of the placebo group. This effect was also dose-dependent and significantly different 
between the supplemented groups. 
Summing up, HMOs have a crucial role in the development of formula-fed infants’ 
gut microbiota, leading to increased levels of beneficial bacteria, particularly Bifidobacteria. 
It should be noted, however, that differences in one or more studies’ results may show up 
but the complex gastrointestinal microbiota must always be taken into account. Also, it is 
important to keep in mind that genetic differences among infants are likely to also influence 
initial colonization and response to prebiotics and that all the results are based on bacterial 
counts on faecal samples as we know, for a fact, that these don’t represent 100% accurately 
what goes on in the gut. 
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4. In Vitro Models 
 
As mentioned, the majority of studies of the gut microbiota are based on bacterial 
counts on faecal samples. Because of this, the results are not able to provide us insights into 
dynamic microbial processes and functionality or digestion at their locations in the gut 
(Verhoeckx et al., 2015). For this purpose, in vitro fermentative models were developed as 
simulators of the ecology of the human colon offering possibilities of studying the 
interactions of substrates or strains with the native colon microbiota´s metabolic activity 
(production of SCFA, gases, enzymes, bacteriocins, etc.) and composition, without any 
ethical constraint (Alander et al., 1999). 
In vitro models comprise two different types of models: batch and continuous 
models, both aiming microbial modulation and metabolism studies, resorting to controlled 
environmental conditions (Verhoeckx et al., 2015). 
 
4.1 Batch Models 
Batch models usually consist of closed-bottles incubations in anaerobic conditions 
using dense faecal microbiota. This is a simple way of characterizing the effect of substrates 
on microorganisms’ physiology and biodiversity and, for that reason, is commonly used as 
a first assessment of the types of microbial metabolites formed (Verhoeckx et al., 2015).  
Batch models are often applied when we want to check for inter-individual variability in the 
response to a particular substrate or for comparison after exposure to different compounds 
or doses of the same compound (Verhoeckx et al., 2015). This model’s implementation on 
longer simulations is not recommended because batch cultures are static and conditions may 
not be physiologically relevant at late time points (Aura et al., 2006). 
 
4.2 Dynamic Models  
The inclusion of host digestive functions in vitro, coupled with multistage continuous 
fermentation modelling, represents the most advanced attempt, thus far, at simulating 
interdependent physiological functions within the human gut (Payne et al., 2012). In this 
way, is now possible to study gut microbiota’s long-term responses to substrates regarding 
metabolic activity and microbial community’s variation. 
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Today, the main examples of continuous fermentation models are the TIM-2, a 
proximal colon simulator, and the SHIME (Verhoeckx et al., 2015). 
 
i. SHIME  
The SHIME® (Simulator of the Human Intestinal Microbial Ecosystem), 
schematized in Figure 8, is a five- stage sequential batch mode reactor system, operated at 
37ºC, simulating the different parts of the gastrointestinal tract, based on the model 
developed by Molly and colleagues, in 1994 (Bianchi et al., 2014). The first two reactors 
simulate the stomach and small intestine, respectively, both being connected to a three-stage 
large intestinal model simulating the lower (ascending, transverse and descending colons) 
digestive tract  (Payne et al., 2012). 
 
 
 
 
 
 
 
 
 
Figure 8 – Basic schematization of the Simulator of Human Intestinal Microbial Ecosystem (SHIME) (edited from 
prodigest.eu).  
 
All reactors consist of double-jacketed glass vessels that are connected through 
peristaltic pumps. A defined nutritional medium (feed), composed of complex carbohydrate 
and protein sources with addition of mucins and a mineral and vitamin mix, is added three 
times a day to the stomach, in the same way as pancreatic and bile liquid (pancreatic juice) 
are added to the small intestine (Wiele et al., 2015). Upon digestion, the slurry is pumped 
into the ascending colon vessel where colon digestion is initiated, while all vessels are 
continuously mixed with magnetic stir bars, pH controlled and kept anaerobic by daily 
flushing the headspace of the respective compartments with N2 gas (Wiele et al., 2015).  
Acids 
Pancreatic Juice 
Food 
Stomach Small 
Intestine 
Ascending Transverse Descending 
Colon 
Waste 
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Because of the inaccessibility of the human colon region to take a representative 
microbial inoculum, faecal microbiota is chosen as inoculum to the colon compartments of 
the SHIME reactor. However, the idea of the SHIME system is to allow a suitable adaptation 
period for the faecal microbiome to adapt to the conditions that prevail in the respective 
colon compartments, so it can be the most accurate possible. Faecal samples are usually 
provided by a single individual due the enormous functional redundancy of the gut 
microbiome. This redundancy makes a pooled microbiome take on a fermentation profile 
very similar to the microbial fermentation profile of a single individual. 
A typical SHIME experiment consists of four stages: stabilization, control, treatment 
and wash-out. During the stabilization period, a strict control of environmental conditions 
(e.g. nutrients, residence time, pH, temperature) is applied, in order to the human faecal 
inoculum evolve to a stable in vitro microbiota that is representative for the different colon 
regions of interest. A stabilization of the microbiota in terms of composition and metabolic 
activity is assured during the control period. Then, a specific alteration is applied to the 
system (treatment). From that moment, changes on the results observed are due to this new 
condition to which the microbiota is subjected. The wash-out period serves to determine how 
long the changes induced can still be measured after the treatment. In the end of a project, 
for a SHIME evaluation, general fermentation activity and metabolic potency are analysed, 
together with microbial composition of each colon vessel. Figure 9 displays a hypothetical 
example of a specific feature of bacterial metabolic activity changing throughout the 
different periods. 
 
Figure 9 - Hypothetical example of microbial activity throughout a SHIME experiment. Upon inoculation of the fecal 
sample, the community is stabilizing resulting in variable metabolite levels. After 2 weeks, a steady-state is reached. At 
this point, the gut microbiome will only change when a treatment is initiated, allowing to establish causal relationships. 
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In order to investigate two different compounds at the same time, a TWINSHIME 
setup was developed by operating two systems in parallel at the same time (Van den Abbeele 
et al., 2010). Identical environmental conditions for both systems are obtained by identical 
pH, liquid transfer and temperature control.  
Van den Abbeele et al. (2013) optimized the SHIME for mimicking mucosal 
microbial colonization by incorporation of mucin-covered microcosms. Using this new 
mucosal M-SHIME version, the author concluded that colonization of the mucosal 
environment was characterized by a higher abundance of butyrate producing Clostridium 
clusters IV and XIVa. Also, he demonstrated that the M-SHIME was able to maintain the 
unique features of an individual’s microbiome in terms of its mucosal composition. 
By altering some of the conditions or the structure, the SHIME can also be refined 
according to the subject being studied. De Boever et al. (2001) developed the Baby SHIME, 
destined to the study of gastrointestinal microbiota of infants. 
The SHIME model has been validated across the years. The first validation coming 
from Molly et al. (1994), in which the authors compared fermentation profiles from a 
SHIME experiment with fermentation profiles from incubations with faecal microbiota from 
human volunteers. Since then, a couple of new validation papers have also been published, 
in 2006 and 2013, respectively (Possemiers et al., 2006; Van den Abbeele et al., 2013).  
 In Table 4 are presented advantages and disadvantages of the SHIME system. 
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Table 4 - Advantages and disadvantages to the SHIME system (edited from Wiele et al., 2015). 
 
  
A
d
v
a
n
ta
g
es
 
 Integrates the entire gastrointestinal tract; 
 Microbiome inoculation from different target groups: adult vs. infant, healthy 
vs. diseased and animals; 
 Colon-region specific research; 
 Maintains microbiome stability over a long timeframe: possibility to monitor 
microbiome adaptation; 
 Mechanistic research by multi-parametric control; 
 Differentiation between mucosal and luminal microbiome in M-SHIME; 
 Parallel control and treatment in TWIN-SHIME setups; 
 Inter individual variability can be studied in a SHIME setup as unique features 
of an individual’s microbiome are preserved. Limiting microbiome simulation 
to one colon region, eight different subjects can be simultaneously assessed. 
D
is
a
d
v
a
n
ta
g
es
  Conventional SHIME setup lacks dialysis. Incorporation of dialysis modules 
is possible after small intestine digestion and colon digestion; 
 Lack of peristalsis; 
 Absence of host cells in conventional SHIME. Solved by coupling to HMI 
module with epithelial or immune cells. 
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II. AIM 
 
In order to provide infants that do not receive breast-feeding with the best possible 
alternative formula feeding, this study aims to test a new human milk oligosaccharide 
(NMO) via gastrointestinal in vitro experiments. Firstly, resorting to short term experiments 
using faecal samples of 10 different babies, the intention was to understand how many 
donors responded positively to the treatment. This response was evaluated based on multiple 
endpoints specifically the pH, the SCFAs concentration and the Bifidobacterium spp. 
concentration and composition. 
Subsequently, one donor inoculum was selected for a long-term baby M-SHIME 
experiment, making this second part of the project only exploratory. During this experiment, 
the NMO was compared to a ‘golden standard’ (GS) oligosaccharide. The evaluation of the 
results was based on the same endpoints as the previous experiment plus the lactate and 
ammonium concentrations, the base-acid consumption and the Bacteroidetes, Firmicutes, 
Lactobacilli and Enterobacteriaceae concentrations and compositions. 
For confidential reasons both tested products cannot be identified. 
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III. MATERIALS & METHODS 
 
1. Fed Batch 
100 mL of buffer were added to 7.5 g of fresh faecal inoculum from each donor, 
followed by a vigorous mixing in the stomacher, for 2 min, and centrifugation for 2 min at 
500 G. The supernatant was collected.   
From the inoculum suspension, 40 mL were added to 10 mL of anaerobic 
cryoprotectant, well mixed in the vortex and distributed over 5 tubes. The tubes were then 
placed in liquid nitrogen at -80ºC, for preservation of the inocula. 
Previous to the start of the batch, 30 penicillin bottles were filled with 63 mL of colon 
medium and incubated at 37ºC and 90 rpm, for 15 min. To each bottle, 7 mL of faecal 
inoculum were added. To 20 bottles (2 bottles per donor), 350 mg of the tested product were 
added - treatment bottles – for a final concentration of 5 g/L (Table 18, Appendix I). The 
bottles were flushed to create anaerobic conditions. Then, at different time points (0h, 24h 
and 48h), 4 mL samples were collected from each bottle for pH quantification, DNA 
extraction and SCFA analysis. Other 8 mL samples were also collected as backup.  
 
2. Baby M-SHIME 
The reactor setup was adapted from the SHIME® (ProDigest and Ghent University, 
Ghent, Belgium), in order to represent the GIT of the human baby, as described by De 
Boever et al. (2001). For these experiment, a baby M-SHIME setup was started operating 
seven proximal colons (PCs) at the same time (5 + 2 as backup that were later excluded), in 
order to obtain identical environmental conditions. Two extra Stomach/Small Intestine 
(S/SI) reactors were added. The whole setup, respectively showed and schematized in 
Figures 10 and 11, was autoclaved. 
Before starting, the seven colon vessels were filled with 140 mL of autoclaved L-
SHIME 6A nutritional medium (or feed) (Table 19, Appendix II). Taking into account the 
absence of absorption in small intestine, the feed included “pre-digested and pre-absorbed” 
milk compounds in the medium rather than raw infant formula. Once the pH of the vessels 
reached values in the range of 5.4 and 5.6, 10 mL of the bacterial inoculum (donor 10) was 
introduced. Two times per day, feed and pancreatic juice (PJ) (12.5 g/L NaHCO3 (Difco), 4 
g/L bile salts (Difco) and 0.9 g/L pancreatin (Sigma Aldrich®)) were added to the S/SI 
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compartments, and then transferred to each vessel. In each cycle, an equal amount was taken 
out of the vessel as waste. In this way, the final residual time was 12 hours. All the vessels 
were kept anaerobic by flushing them with N2, were continuously stirred (300 rpm) and kept 
at constant temperature (37ºC) and pH (5.6-5.8). Over a period of twenty days, every two 
days, content from each vessel was collected always at the same time and stored at -20ºC for 
metabolic and microbial analysis.  
Just as a M-SHIME, additionally, each PC included a mucus compartment as the 
inclusion of a mucus layer increases the relevance of the simulation and proved to deliver 
additional results. The presence of the mucus appears to be an important factor for 
Bifidobacteria, including Bifidobacterium longum subsp. infantis (Kavanaugh et al., 2013; 
Muñoz et al., 2011; D. A. Sela et al., 2008), potentially providing this strain a selective 
advantage in colonizing the gastrointestinal tract.  
 
 
 
 
 
 
Figure 10 – Baby M-SHIME set-up used to grow bacterial communities. A computer controlled set-up of nine vessels 
was assembled. 1,2 – stomachs/small intestines; 3-9 – proximal colons; 10 – waterbath (37ºC); 11 – HCl (0,5 M, 
Sigma Aldrich) and NaOH (0,5 M, Sigma Aldrich) soutions to control pH; 12 – feed; 13 – pancreatic juice. 
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The SHIME experiment consisted of the following phases: 
 Start-up period, after inoculation of the colon reactors with faecal material 
from selected donor. This period allowed the microbial community to 
differentiate in the different reactors depending on the local environmental 
conditions. At the end of this period, two of the seven PC vessels were 
removed from the system since their conditions (SCFA, pH) were not similar 
to the rest. 
 Control period, which allowed to determine the baseline microbial 
community composition and activity in the different reactors. This baseline 
was used as control to compare with the results from the prebiotic treatment. 
During this period, 0.1 g/L of the test products (GS and NMO) were added to 
both feed containers to prevent wash-out of microbes that are potentially 
specialized in degrading these compounds prior to the start of the 2-week 
treatment; 
 Treatment period, in which the basic diet was amended with the specific test 
product(s) (3.2 g/L) to evaluate its impact on the composition and activity of 
the gut microbiota. In Table 5 are indicated the amounts GS and NMO in each 
PC. 
 
 
 
 
 
Figure 11 – Scheme of the baby M-SHIME set-up. GS – “Golden standard” feed (3.2 g/L); NMO – “New Milk 
Oligosaccharide” feed (3.2 g/L); PJ – pancreatic jJuice; A,B – stomachs/small intestines; 1-5 – proximal colons (other 
two vessels were excluded); W – waste container. 
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Table 5 – Percentage of each test product (“Golden Standard” and New Milk Oligosaccharide) on every PC. 
 
 
 
 
 
 
 
 
 
 
3. Metabolic Analysis 
 
3.1 SCFAs 
For the analysis of SCFA acetate, propionate and butyrate, the method described by 
De Weirdt et al. (2010) was applied. Briefly, SCFAs were extracted from the samples with 
diethyl ether, after the addition of 2-methyl hexanoic acid as an internal standard. Extracts 
were analysed using a GC-2014 gas chromatograph (Shimadzu®, ‘s-Hertogenbosch, 
Netherlands), equipped with a capillary fatty acid-free EC-1000 Econo-Cap column 
(Alltech®, Laarne, Belgium), a flame ionization detector and a split injector. The injection 
volume was 1 µL and the temperature profile was set from 110 to 160°C, with a temperature 
increase of 6 °C/min. The carrier gas was nitrogen and the temperature of the injector and 
detector were 100 and 220 °C, respectively. 
 
3.2 Lactate 
For the lactate analysis, a D-lactic/L-lactic acid kit (Bioline®, London, UK) was 
used. All the steps made were taken following the guidelines from the kit. At first, the 
absorbance (A1) of a mix of 50 µL of sample and 1060 µL of master mix was measured at 
340 nm, using a UV-1800 spectrophotometer (Shimadzu). Subsequently, D-lactate 
dehydrogenase (D-LDH) and D-glutamate pyruvate transaminase (D-GPT), were added as 
a mixture (10 µL per sample) to induce the next reactions: 
 
PC 
Feed 
‘Golden 
Standard’ 
New Milk 
Oligosaccharide 
1 100 % 0 % 
2 90 % 10 % 
3 75 % 25 % 
4 50 % 50 % 
5 0 % 100 % 
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𝐷 − 𝑙𝑎𝑐𝑡𝑎𝑡𝑒 +   𝑁𝐴𝐷+     ↔     𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 +  𝑁𝐴𝐷𝐻 +  𝐻+    
𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 +  𝐷 − 𝑔𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒     ↔     𝐷 − 𝑎𝑙𝑎𝑛𝑖𝑛𝑒  +   2 − 𝑜𝑥𝑜𝑔𝑙𝑢𝑡𝑎𝑟𝑎𝑡𝑒    
 
This two steps reaction consists in the conversion of D-lactate into pyruvate (1), 
which in turn is converted into D-alanine (2). After 30 minutes the absorbance (A2) is 
measured at 340 nm. In order to convert the remaining lactate (L-lactate), another 10 µL 
mixture of L-LDH and L-GTP was added to each sample. The following reactions occurred: 
 
 𝐿 − 𝑙𝑎𝑐𝑡𝑎𝑡𝑒 +   𝑁𝐴𝐷+     ↔     𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 +  𝑁𝐴𝐷𝐻 +  𝐻+     
 𝑝𝑦𝑟𝑢𝑣𝑎𝑡𝑒 +  𝐿 − 𝑔𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒     ↔     𝐿 − 𝑎𝑙𝑎𝑛𝑖𝑛𝑒  +   2 − 𝑜𝑥𝑜𝑔𝑙𝑢𝑡𝑎𝑟𝑎𝑡𝑒     
 
The absorbance (A3) was measured at 340 nm. 
Total, D and L-lactate concentrations (g/L), 𝑐, were determined using the following 
equation: 
 
𝑐 =
𝑉 × 𝑀𝑊
1000 × 𝜀 × 𝑑 × 𝑣
∆𝐴 
 
Where 𝑉 is the final volume, 𝑣 is the sample volume, 𝑀𝑊 is the molecular weight 
of lactate, 𝑑 is the light path, ∆𝐴 is the difference in absorbance and 𝜀 is the extinction 
coefficient of NADH at 340 nm. 
 
3.3  Ammonium 
The ammonium analysis was performed using the FoodALYT D 5000 Steam 
Distillation Unit (Omnilab®, Bremen, Germany) complemented with Doorstroomkoeler 
Fryka DLK 602 cooling system (Voor‘t Labo®, Eeklo, Belgium) set at 10ºC. The 
ammonium was distilled in a slightly alkaline medium (MgO (ChemLab®, Zedelgem, 
Belgium)), in the form of ammonia and absorbed in 10 mL boric acid (Chem Lab) mixed 
indicator (pH 5.3). The ammonia in the distillate, now in the form of borate ((NH4)3BO3) 
was determined titrimetrically with HCl (0.02 N) (VWR) using the Titroline (Omnilab). 
The content of NH4
+-N is calculated with following formula: 
D-LDH 
D-GTP 
L-LDH 
L-GTP 
 30 
 
 
𝑁𝐻4
+– 𝑁 (
𝑚𝑔
𝐿
) =
(𝐴 − 𝐵) × 0,02 × 14,01 × 1000 × 𝑓
𝑉𝑠𝑎𝑚𝑝𝑙𝑒
 
 
Where 𝐴 is the volume of HCl titrated for the sample (mL), 𝐵 is the volume of of 
HCl titrated for the blank (mL), 𝑉𝑠𝑎𝑚𝑝𝑙𝑒 is the volume of sample (mL) and 𝑓 is the dilution 
factor. 
  
 
4. Microbial Analysis 
 
4.1 DNA Extraction 
Total DNA was extracted using the Fast-Prep24 instrument (Mp-Bio®, Eschwege 
Germany), as previously described by Vilchez-Vargas et al. (2013). Briefly, for DNA 
extraction, the pellet of 1 mL of liquid sample or 0.25 g of mucus samples were re-suspended 
in 1 ml Tris/HCl (100 mM pH 8.0), supplemented with 100 mM EDTA, 100 mM NaCl, 1% 
(wt/vol) polyvinylpyrrolidone and 2% (wt/vol) sodium dodecyl sulphate and transferred to 
a 2 ml eppendorf tube containing 0.2 g beads (for the mechanical disruption). Cells were 
lysed in the Fast Prep-24 instrument (40 sec, 6.0 m/sec). Samples were centrifuged at 14000 
G for 1 min at 4°C and the supernatant washed with one volume phenol/chloroform (1:1), 
centrifuged and the aqueous phase washed with one volume chloroform. After 
centrifugation, nucleic acids (aqueous phase) were precipitated with one volume of ice-cold 
isopropanol and 1:10 volume of 3 M sodium acetate. Next, the DNA was precipitated with 
three volumes of ethanol and 1:10 volume of 3 M sodium acetate. After centrifugation and 
washing with 80% ethanol the pellet was re-suspended in 50 ml of milliQ water. DNA 
quality and quantity were analysed electrophoretically on a 1% (w/v) agarose gels and 
spectrophotometrically by determination of the absorbance at 260 nm and the absorbance 
ratios at 260 nm and 280 nm, respectively. 
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4.2 Denaturing Gradient Gel Electrophoresis (DGGE) 
DGGE profiling was used to monitor the most prominent shifts within the 
bifidobacterial microbial community. After DNA extraction and PCR with group-specific 
primers, DGGE was performed to separate PCR products (Table 5). Gels were run using a 
DCodeTM Universal Mutation Detection System (Bio-Rad®, Nazareth, Belgium) and data 
analysis was carried out using GelCompar version 6.6 (Applied Maths®, Sint-Martens-
Latem, Belgium). Pearson correlation and UMPG clustering were used to calculate 
dendrograms of DGGE profiles. 
 
Table 6 - PCR conditions and DGGE protocol for the investigated bacterial group. 
Bacterial group PCR primers PCR protocol DGGE protocol Reference 
Bifidobacteria * BIF164f 
BIF662r 
7’ 95 °C; 35 x (1’ 94 
°C/1’ 62 °C/2’ 72 °C); 10’ 
72 °C 
50-65%, 8%, 
16h, 38V, 60°C 
(Satokari et 
al., 2001) 
* The PCR product of the group-specific PCR was diluted 1:100 
 
4.3 Quantitative Polymerase Chain Reaction (qPCR) 
A culture-independent method (qPCR) was applied to quantify Bifidobacteria. 
Specific primers, temperature conditions and primer concentrations can be found in Table 6. 
The PCR mixtures (total volume of 15 µL) contained 5µL template (between 1 -10 µg/µL 
DNA, corresponding to a 1:100 dilution of the original DNA extract) and 10µL QPCR 
SYBR Green ROX Mix (Westburg®, Leusden, Netherlands), forward and reverse primer 
(10 µM each). Negative controls for each batch of samples included template consisting of 
qPCR water. Samples were incubated in a StepOnePlus real-time PCR device (Applied 
Biosystems®, Bleiswijk, Netherlands). Each sample was analysed in triplicate. Samples 
were checked for correct peaks in the melt curve. The standard curve in all of the different 
runs should have an efficiency between 90-105%. If not, the run was repeated. Outliers 
(more than 1 CT difference) in triplicates were omitted. Resulting values were converted to 
copies/µL by multiplying with 102, i.e. by taking into account the dilution (there was a 1:100 
dilution of DNA extract prior to the qPCR).  
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Table 7 - qPCR conditions for the investigated bacterial groups. 
Bacterial group PCR primers PCR protocol 
Primer 
(µM) 
Bifidobacteria* 
Bif243F (TCGCGTCYGGTGTGAAAG) 
Bif243R 
(CCACATCCAGCRTCCAC) 
15’ 95 °C; 40 x (1’ 95 °C/1’ 58 
°C/1’45” 72 °C); 
15” 95°C; 20” 70°C; 15” 95°C 
0.5 
 
Lactobacilli 
F_Lacto_05 
(AGCAGTAGGGAATCTTCCA) 
R_Lacto_04 
(CGCCACTGGTGTTCYTCCATATA) 
15’ 95 °C; 40 x (15” 95 °C/1’ 
60°C); 
15” 95°C; 20” 70°C; 15” 95°C 
0.3 
Firmicutes 
Firm934F 
(GGAGYATGTGGTTTAATTCGAAGCA) 
Firm1060R 
(AGCTGACGACAACCATGCAC) 
15’ 95 °C; 40 x (15” 95 °C/1’ 
60°C); 
15” 95°C; 20” 70°C; 15” 95°C 
0.3 
Bacteroidetes 
Bact 934F 
(GGARCATGTGGTTTAATTCGATGAT) 
Bact 1060R 
(AGCTGACGACAACCATGCAG) 
15’ 95 °C; 40 x (15” 95 °C/1’ 
60°C); 
15” 95°C; 20” 70°C; 15” 95°C 
0.3 
Enterobacteria 
Ent-F 
(GTTGTAAAGCACTTTCAGTGGTGAGG
AAGG) 
Ent-R 
(GCCTCAAGGGCACAACCTCCAAG) 
15’ 95 °C; 40 x (15” 95 °C/1’ 
60°C); 
15” 95°C; 20” 70°C; 15” 95°C 
0.3 
* Remark = 1 µL MgCl2 were added to 1 mL of the original buffer 
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IV. BATCH EXPERIMENT 
 
1. Results 
 
Donors 1, 3, 6 and 8 
Tables 7, 8, 9 and 10 present the pH and SCFA values of control and treatment at 0h, 
24h and 48h after inoculation, for donors 1, 3, 6 and 8, respectively. All of them indicate a 
decreased pH over time with both treatment and control, though more pronounced with 
treatment. The four donors showed a high increase of acetate with the treatment. Further, 
while in donors 1 and 3 the propionate increase was not significant even with treatment, 
donors 6 and 8 showed the highest amounts among all the 10 donors. Butyrate concentrations 
resulting from treatment were generally very low. 
Figures 10, 11, 12 and 13 display the quantitative and qualitative alterations in the 
Bifidobacteria population of each donor. By comparing inoculum with 48h bottles, a higher 
growth was observed when the treatment was applied, although no alterations were observed 
in the microbiotas’ structure as assessed with DGGE. Donor 6 was the only exception, 
showing a few differences in terms of abundance of some strains. 
 
 
 Table 8 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 1. 
 
 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.36 6.34 ± 0.01 0.6 0.0 0.0 
24h 6.09 4.48 ± 0.00 7.5 22.6 ± 0.3 2.5 0.0 ± 0.0 0.0 0.0 ± 0.0 
48h 6.19 4.39 ± 0.00 10.2 25.2 ± 0.3 3.4 0.0 ± 0.0 0.8 0.0 ± 0.0 
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Table 9 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 3. 
 
 
 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.35 6.30 ± 0.03 1.8 0.0 0.0 
24h 5.92 4.47 ± 0.00 8.1 28.7 ± 0.24 0.2 0.0 ± 0.0 0.0 0.0 ± 0.0 
48h 6.11 4.44 ± 0.01 8.8 29.2 ± 0.38 0.3 0.0 ± 0.0 0.0 0.0 ± 0.0 
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Figure 13 – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at the 
beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment using 
faecal material of donor baby 3. 
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Figure 12 – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at the 
beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment using 
faecal material of donor baby 1. 
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Table 10 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 6. 
 
 
 
 
Table 11 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 8. 
 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.44 6.37 ± 0.02 0.6 0.2 0.1 
24h 6.17 4.76 ± 0.08 8.8 20.1 ± 0.4 3.1 18.6 ± 0.2 1.7 0.1 ± 0.0 
48h 6.32 4.91 ± 0.00 9.8 20.7 ± 0.1 3.4 18.6 ± 0.0 2.0 0.1 ± 0.0 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.44 6.38 ± 0.01 1.0 0.1 0.1 
24h 6.14 4.97 ± 0.00 8.7 27.5 ± 1.2 2.0 7.2 ± 0.3 0.9 0.2 ± 0.0 
48h 6.15 4.99 ± 0.00 11.4 26.6 ± 0.1 2.1 7.3 ± 0.1 2.0 0.2 ± 0.0 
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Figure 14 – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at the 
beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment using 
faecal material of donor baby 6. 
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Donors 2, 4 and 5 
Tables 11, 12 and 13 present the pH and SCFA values of the control and treatment 
at 0h, 24h and 48h after incubation, for donors 2, 4 and 5, respectively. All of them show a 
small decrease in pH over time in both treatment and control. When compared with the rest 
of the donors, these three donors showed low increases in acetate, propionate and butyrate 
upon dosing the treatment.  
Figures 14, 15 and 16 display the quantitative and qualitative alterations in the 
Bifidobacteria population of each donor. While donors 4 and 5 had a very low number of 
Bifidobacteria in the inoculum, control and treatment, donor 2 even revealed a decrease over 
time. No alterations were observed in the microbiota’s composition of the three donors.  
 
Table 12 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 2. 
 
 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.38 6.30 ± 0.01 0.3 0.0 0.0 
24h 6.00 6.09 ± 0.08 4.8 5.8 ± 0.0 1.4 1.8 ± 0.0 0.5 0.4 ± 0.0 
48h 6.29 6.08 ± 0.08 7.2 10.8 ± 0.2 1.7 3.1 ± 0.0 1.4 1.2 ± 0.0 
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Figure 15 – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at the 
beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment using 
faecal material of donor baby 8. 
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Table 13 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 4. 
 
 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.38 6.37 ± 0.02 0.5 0.1 0.0 
24h 6.27 6.21 ± 0.01 5.5 7.0 ± 0.0 1.3 1.7 ± 0.0 1.1 1.2 ± 0.0 
48h 6.34 6.18 ± 0.04 7.1 10.3 ± 0.1 1.5 2.4 ± 0.0 1.5 1.5 ± 0.0 
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Figure 17 – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at the 
beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment using 
faecal material of donor baby 4. 
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Figure 16  – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at 
the beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment 
using faecal material of donor baby 2. 
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Table 14 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 5. 
 
 
Donors 7, 9 and 10 
Tables 14, 15 and 16 present the pH and SCFA values of the control and treatment 
at 0h, 24h and 48h after incubation, for donors 7, 9 and 10, respectively. These three donors 
show a decrease in pH over time with both treatment and control, though more pronounced 
with treatment. They all showed increases of acetate, propionate and butyrate concentrations 
upon dosing the treatment. The most relevant value is the butyrate concentration of donor 
10, which reached 3.9 mM after 48 h, the highest between all donors.  
Figures 17, 18 and 19 display quantitative and qualitative alterations in the 
Bifidobacteria population of each donor. These three donors showed the highest increase of 
Bifidobacteria or presented the largest differences treatment vs inoculum. Donor 10 was the 
only one showing alterations in the bifidobacterial composition, with a specific increase of 
a band that was identified as Bifidobacterium longum spp. infantis. 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.28 6.39 ± 0.02 0.1 0.0 0.0 
24h 6.23 6.14 ± 0.02 3.6 4.1 ± 0.1 1.7 2.0 ± 0.0 0.0 0.0 ± 0.0 
48h 6.29 6.27 ± 0.00 3.9 5.0 ± 0.1 2.4 3.6 ± 0.0 0.0 0.0 ± 0.0 
Figure 18 – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at the 
beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment using 
faecal material of donor baby 5. 
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Table 15 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 7. 
 (Note: Control values at 24h and 48h were not possible to obtain) 
 
 
 
 
Table 16 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 9. 
 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.44 6.47 ± 0.01 0.9 0.1 0.2 
24h NA 4.68 ± 0.00 NA 34.1 ± 0.2 NA 4.8 ± 0.0 NA 2.0 ± 0.0 
48h NA 4.67 ± 0.04 NA 31.9 ± 0.3 NA 4.5 ± 0.0 NA 1.9 ± 0.0 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.39 6.39 ± 0.02 0.7 0.1 0.1 
24h 6.16 4.43 ± 0.02 10.8 28.7 ± 0.9 5.1 4.5 ± 0.2 1.3 0.2 ± 0.0 
48h 6.23 4.48 ± 0.01 10.1 27.7 ± 0.2 5.4 4.9 ± 0.0 1.8 0.2 ± 0.0 
Inoculum
Treatment A
Treatment B
2,6E+03 5,1E+03
3,1E+04
0,0E+00
5,0E+03
1,0E+04
1,5E+04
2,0E+04
2,5E+04
3,0E+04
3,5E+04
4,0E+04
4,5E+04
5,0E+04
Inoculum Control Treatment
0h 48h
B
if
id
o
b
a
ct
er
ia
 (
co
p
ie
s/
µ
L
)
4,5E+03
2,3E+03
1,3E+04
B
if
id
o
b
a
ct
er
ia
 (
co
p
ie
s/
µ
L
)
Bifido_DGGE_2015
1
0
0
9
8
Bifido_DGGE_2015
.
.
.
Baby 7
Baby 7
Baby 7
Inoculum
FL1
FL2
9,9E+03
2,0E+04
4,1E+04
B
if
id
o
b
a
ct
er
ia
 (
co
p
ie
s/
µ
L
)
Figure 19 – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at the 
beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment using 
faecal material of donor baby 7. 
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Table 17 – Average pH and SCFAs’ concentrations (± SD) (mM) obtained at different time-points (0h, 24h, 48h) from 
inoculum, control and treatment bottles of the batch experiment using faecal material of donor baby 10. 
 
 pH Acetic Acid Propionic Acid Butyric Acid 
 Ctrl Treat Ctrl Treat Ctrl Treat Ctrl Treat 
0h 6.41 6.42 ± 0.03 0.1 0.0 0.0 
24h 5.62 5.49 ± 0.00 5.3 7.0 ± 0.2 1.6 1.7 ± 0.1 0.9 3.3 ± 0.2 
48h 5.84 4.28 ± 0.00 6.7 22.7 ± 0.5 2.8 2.8 ± 0.0 1.6 3.9 ± 0.1 
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Figure 21 – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at the 
beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment using 
faecal material of donor baby 10. 
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Figure 20 – Absolute Bifidobacteria numbers (left: copies/µL) and qualitative changes within the bifidobacterial community (right) at the 
beginning and end of the incubation (48h), both for the control and the treatment. Values were obtained from a batch experiment using 
faecal material of donor baby 9. 
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2. Discussion 
 
For the selection of one donor out of the ten donors, results were analysed and 
compared to choose the one with the best response to treatment.  
 
pH 
This feature gave a first insight in the overall bacterial growth/activity during the 
incubations, since the latter results in a decreased pH due to the accumulation of produced 
acids, such as SCFAs. 
Figure 20 provides an overview of the pH differences after 24 and 48 hours, between 
the inoculum and both the treatment and the control, for all the 10 donors. After 48 hours, 
all donors responded with decreased pH, although not relevant in case of donors 2, 4 and 5. 
On the other hand, donors 1, 3, 6, 7, 8, 9 and 10 showed an appreciable decrease. Donor 10 
had the lowest pH and was the only one who presented a clear decrease after 24 hours 
indicating a slower initial degradation. This can be either because the inoculum contained 
less bacteria or bacteria responsible for breakdown were less abundant, requiring more time 
to grow. Then again, if we compare the control results of donor 10 with the other lower 
controls we can also suggest that this donor had a much richer microbiota. This could have 
been known if a full analysis of the microbiota present in the inocculum had been done.  
Figure 22 - pH differences between the inoculum and both treatment and control (24h and 48h bottles) obtained 
from batch experiment. (Note: control values of baby 7 are averages of control values of all the other donors.) 
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SCFAs 
The concentrations of each SCFA were also determined concerning the metabolic 
activity of bacteria. Figure 21 shows the overview of the difference between treatment and 
control after 48 hours. First, point out that all donors, except 2, 4 and 5, showed high 
production of acids, proving a good correlation with the aforementioned pH results. The 
acetate production was very similar among the different donors tested, reaching higher 
values when the treatment was applied, with improvements ranging from around 10 mM up 
to almost 25 mM. With respect to propionate, seven out of ten donors also had better acids 
production with the treatment, from which donors 6 and 8 stand out (around 15 and 5 mM, 
respectively). Finally, donors 7 and 10 showed an enhancement in butyrate production with 
treatment, increasing 2.24 mM over control in the latter. As already mentioned, the 
production of butyrate by a microbiota can be linked to presence of Bifidobacteria due to the 
process of cross-feeding.  
As a remark, applying the treatment to donors 7, 6 and 10 resulted in the highest 
concentrations of acetate (31.9 mM), propionate (18.6 mM) and butyrate (3.9 mM), 
respectively. 
 
 
Figure 23 – Differences of acetate, propionate and butyrate concentrations between treatment and control 48h 
bottles. Values were obtained in a batch experiment. (Note: For the control values of baby 7, an average of all the 
other control bottles was used) 
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Bifidobacteria 
Finally, the bifidobacterial community was analysed quantitatively and qualitatively. 
Figure 22 shows the overview of the difference of the absolute number of Bifidobacteria 
between treatment and control after 48 hours. All donors, except 2, 4 and 5, indicated higher 
growth in treatment bottles, with donors 7 and 9 showing the most marked increase, followed 
by donors 8 and 10. The first group obtained a difference between 2.5E04 and 3.0E04 
copies/µL, while the latter had a difference between 1.0E04 and 1.5E04 copies/µL.  
With respect to the bifidobacterial composition, donor 10 was the only donor 
showing differences between the treatment and the control that were observable in the 
DGGE pictures. Although sequencing and identification have yet to be done, from previous 
projects of ProDigest we know that the new central darker band appearing with treatment 
(Figure 19) is due to the presence of Bifidobacterium longum spp. infantis, a common species 
in a healthy breast-fed infants’ gut microbiota.  
 
 
B. infantis was already shown to have a 43-kb gene cluster (HMO cluster I) encoding 
a variety of oligosaccharide transport proteins, glycoside hydrolases (fucosidases, sialidases, 
β-hexosaminidase and β-galactosidase) and permeases, all predicted to hydrolyse and 
internalize human milk-derived oligosaccharides thereby generating monosaccharides 
(Ventura et al., 2015). This gene cluster is not found in other bifidobacterial species. 
Figure 24 – Difference of the bifidobacterial concentration (copies/mL) between treatment and control 
48h bottles. Values were obtained from a batch experiment. 
 44 
 
Moreover, only B. infantis, the archetypical HMO-utilizing bacterium, is able to digest all 
HMO structures  (Underwood et al., 2015). 
When grown in the presence of HMOs, B. infantis strains upregulate the expression 
of the gene encoding for the oligosaccharides transport proteins that bind to specific HMO 
linkages. The same does not happen when an identic strain is grown on the simpler prebiotic 
oligosaccharides FOS or GOS, suggesting that B. infantis is able to transport intact HMOs 
into its cytoplasm and that this capacity is “turned on” by the HMOs (Underwood et al., 
2015). 
B. infantis protective mechanisms are based on its anti-inflammatory and intestinal 
permeability decrease properties, SCFA production and also its increased colonization 
resulting in decreased diversity of the gut microbiota and fewer luminal pathogens 
(Underwood et al., 2015). Furthermore, positive correlations between B. infantis infant gut 
predominance and better weight gain and better responses to oral polio, tuberculosis, and 
tetanus vaccines have already been demonstrated. Still, this correlation does not determine 
the cause and consequence (Underwood et al., 2015). 
In conclusion, donor 10 was selected to proceed with this study taking into account 
the effects caused by the new treatment, namely: the decreasing pH, the increase of SCFAs 
concentration, especially butyrate, and the alterations of the bifidobacterial population with 
the emergence of B. infantis. 
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V. BABY M-SHIME 
 
1. Results 
 
Base-Acid Consumption 
To make sure that optimal environmental conditions were maintained, the pH in the 
baby M-SHIME® system was controlled by pH controllers between 5.4-5.6 in the proximal 
colons (PCs) and the adding of acid and/or base. 
Figure 25 presents the base-acid consumption (mL) per day of every PC (100/0, 
90/10, 75/25, 50/50 and 0/100 of GS/NMO) during control (C1, 2 and 3) and treatment weeks 
(T1, 2, 3, 4, 5 and 6). This graph provides a clear view of the development of this parameter 
over time. All the 5 PCs indicate a stable and similar control week, as expected, and a 
pronounced increase when starting the treatment, at T1. Every PC reaches its peak at T3 (end 
of the 1st treatment week).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 displays the average amount of acid and base consumed (mL) per week. 
Like the previous figure, this graph shows a large increase from control to 1st treatment 
week, for all units. On the other hand, during the 2nd treatment week a slight decrease is 
observed. All units’ base-acid consumptions were very similar excepting for 90GS/10NMO 
Figure 25 - Base-acid consumption (mL) during the control and treatment periods (100/0, 90/10, 75/25, 50/50 and 
0/100 of GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n = 3). 
Note: Control values were normalized. 
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which showed lower values than the rest. Nonetheless, every single PC had a significant 
increase during treatment weeks in comparison with control. 
 
 
SCFAs 
Such as in the batch experiment, the concentrations of each SCFA were also 
determined concerning the metabolic activity of bacteria. Figure 27 shows the absolute 
variance of acetate, propionate, butyrate and total SCFAs concentrations (mM) over time. 
Every PC showed an increase of each SCFA after control week and, like the base-acid 
consumption, peaks were reached at T3 (end of 1st treatment week). Noteworthy, the fact 
that 100NMO got the highest peak of total SCFAs, close to 20 mM, at T3. 
 
 
Figure 26 – Average base-acid consumptions (mL) during the control and treatment weeks (100/0, 90/10, 75/25, 50/50 and 
0/100 of GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n = 3). 
* : difference against control statistically significant (p-value < 0.05). 
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The following figures display the average amount of each SCFA (mM) per week. 
Acetate levels (mM), presented in Figure 28, significantly increased during both 
treatment weeks. Similar to the pre-screening, where mainly acetate increased upon NMO 
treatment, also during the SHIME experiment, acetate was the SCFA that most strongly 
increased upon GS/NMO treatments (~10mM increase vs control). All PCs had significant 
increases during in both treatment weeks, always reaching values above 30 mM. 
 
 
 
 
 
 
 
 
Figure 27 - Acetate, Propionate, Butyrate and total SCFA production during the control and treatment period (100/0, 
90/10, 75/25, 50/50 and 0/100 of GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal 
material of baby 10. Graphs represent the absolute increase in concentration as compared to the average level during 
the control period (mM). Note: Control values were normalized. 
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Figure 28 - Acetate levels (mM) during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of 
GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n = 3). 
* : difference against control statistically significant (p-value < 0.05). 
 
 
  
  
 
 
 
 
 
 
 
 
 
As for propionate levels (mM), exposed in Figure 29, a slight increase was registered 
during the 1st treatment week (~0.5-1.5 mM increase vs control), although this effect was 
temporary as it was not observed during the 2nd treatment week. The highest value, 
specifically 9.1 mM, was obtained by the 100GS during the 1st treatment week. All the others 
were very close to 8.0 mM. 
 
Figure 29 - Propionate levels (mM) during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of 
GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n = 3). 
* : difference against control statistically significant (p-value < 0.05). 
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Butyrate levels (mM), displayed in Figure 30, demonstrated a more accentuated 
increase than propionate, although only during the 2nd treatment week (~2.0 mM increase vs 
control). In the 1st treatment week, there was a tendency to higher values, albeit not 
significantly different from the control period as this increase was gradual (except for 
100GS).  
 
Altogether, total SCFAs (mM) levels, in Figure 31, increased during treatment 
weeks (~12mM increase vs control).  
   
Figure 30 - Butyrate levels (mM) during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of 
GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n = 3). 
* : difference against control statistically significant (p-value < 0.05). 
Figure 31 - Total SCFA levels (mM) during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 
of), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n = 3).  
* : difference against control statistically significant (p-value < 0.05). 
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Lactate  
Lactate analysis is of great interest due to his potential beneficial effects, specifically 
its antimicrobial effect or conversion to butyrate.  
The results of this analysis are exposed in Figure 32 which shows the lactate 
concentration values (mM) of every PC (100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO) 
during control (C1, 2 and 3) and treatment weeks (T1, 2, 3, 4, 5 and 6).   
 
During the two-week treatment period, all the PCs’ profiles were low value (~1.0 
mM) and very stable. However, there were several remarkable peaks upon 90GS/10NMO, 
75GS/25NMO and 50GS/50NMO treatments, with the first two reaching around 2.0 mM 
and the latter, around 3.0 mM. These peaks were observed around the same time-lapse, 
particularly at T1 or T2. 
 
Ammonium and branched SCFAs 
Figure 33 shows the b-SCFA concentration (mM) values of every PC (100/0, 90/10, 
75/25, 50/50 and 0/100 of GS/NMO) during control (C1, 2 and 3) and treatment weeks (T1, 
2, 3, 4, 5 and 6). While there were no significant differences between the control and 
treatment weeks, similar as for lactate, a peak in the production of b-SCFAs was observed 
during the 1st treatment week, at the same time point (T3). The height of the peak increased 
for administration of (almost) pure products (100GS, 100NMO, 90GS/10NMO). When more 
similar ratios of GS/NMO were prepared, like 75/25 and especially 50/50, the peak in b-
SCFAs levels became considerably lower. 
Figure 32 - Lactate levels (mM) during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of 
GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n = 3).     
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Regarding the NH4
+ production, Figure 34 presents its concentration (mg NH4
+-N/L) 
values on every PC (100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO) during control (C1, 
2 and 3) and treatment weeks (T1, 2, 3, 4, 5 and 6). This graph shows these values fairly 
stable over time, being kept between 150 and 200 mg (almost) continuously. Nonetheless, 
throughout the experiment there were some minor changes, with a significant decrease being 
noted for the 50 GS/50 NMO mixture, at T2, as we can see in Figure 35 which displays the 
average amount of ammonium (mg NH4
+-N/L) per week. 
 
Figure 34 - Branched SCFA levels (mM) during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 
of GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n = 3). 
Figure 33 - Ammonium (mg NH4+-N/L) during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of 
GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n per week = 3). 
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Qualitative analysis of the Bifidobacterium community 
composition (DGGE) 
The bifidobacterial community was analysed qualitatively. Figures 37 and 39 show 
the DGGE pictures upon 100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO feeding 
conditions with respect to lumen and mucus sampling, respectively. Both pictures confirm, 
in concordance with the previous pre-screening experiment, that while GS stimulates B. 
longum, NMO increases the abundance of B. longum subsp. infantis. The selective increase 
of a specific Bifidobacterium species by GS and NMO became much clearer upon exporting 
the densities of each OTU from the DGGE profiles. These luminal and mucosal 
bifidobacterial abundances (based on the assumption that bands at the same height as during 
the previous project (2014) correspond with the same OTUs) are exposed in Figures 38 and 
40. 
 
 
 
 
 
 
Figure 35 - Ammonium (mg NH4+-N/L) during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of 
GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n per week = 3).  
* : difference against control statistically significant (p-value < 0.05). 
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Figure 36 - Abundance of four Bifidobacterium species/groups based on the bifidobacterial DGGE profiles of the 
luminal microbiota during the control and treatment periods (100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO), in 
the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n per week = 1). The 
reported phylogeny is based on the assumption that bands at the same height as during the previous project (2014) 
correspond with the same OTUs. 
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Figure 37 - Pearsson correlation of the bifidobacterial DGGE profiles of the luminal microbiota during the control and 
treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO), in the proximal colon (PC) of the baby M-
SHIME, inoculated with faecal material of baby 10 (n per week = 1). The highlighted lanes concern 2nd treatment 
week. The reported phylogeny is based on the assumption that bands at the same height as during the previous 
project (2014) correspond with the same OTUs. 
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Figure 38 - Abundance of four Bifidobacterium species/groups based on the bifidobacterial DGGE profiles of the 
mucosal microbiota during the control and treatment periods (100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO), in 
the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n per week = 1). The 
reported phylogeny is based on the assumption that bands at the same height as during the previous project (2014) 
correspond with the same OTUs. 
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Figure 39 - Pearsson correlation of the bifidobacterial DGGE profiles of the mucosal microbiota during the control and 
treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO), in the proximal colon (PC) of the baby M-
SHIME, inoculated with faecal material of baby 10 (n per week = 1). The highlighted lanes concern 2nd treatment 
week. The reported phylogeny is based on the assumption that bands at the same height as during the previous 
project (2014) correspond with the same OTUs. 
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Quantitative analysis of the Bifidobacterium community 
composition (qPCR) 
Specific qPCRs were selected, all together covering the main phyla/groups present 
in a baby gut microbiota, specifically: Firmicutes, Lactobacilli, Bifidobacterium, 
Bacteroidetes and Enterobacterieceae for luminal communities and the first three for 
mucosal communities. 
A representative overview of the baby’s community was obtained. The luminal 
results are displayed in the pie charts of Figure 40, each chart corresponding to a specific 
combination of GS/NMO at a different week of the experiment (C, TR1 or TR2). 
One of the most remarkable features from these results is the fact that, during the 1st 
treatment week, all treatments tended to increase the Firmicutes and Bifidobacteria at the 
expense of Enterobacterieceae. Moreover, during the 2nd treatment week, NMO seemed to 
expand Enterobacterieceae levels in a dose-related way. 
On the other hand, Figure 41 presents the graphs for the average mucosal abundance 
of Firmicutes, Bifidobacteria and Lactobacilli on every PC (100/0, 90/10, 75/25, 50/50 and 
0/100 of GS/NMO) during control and treatment periods. The three groups were found to 
significantly expand at the intestinal gut wall, preferentially upon dosing higher levels of 
NMO as compared to GS. 
 
 56 
 
 
Figure 40 -  Abundance of Bacteroidetes, Firmicutes, Lactobacilli, Bifidobacteria and Enterobacteria (%) in the luminal microbiota during the control and treatment period (100/0, 90/10, 75/25, 
50/50 and 0/100 of GS/NMO), in the proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of donor 10, as assessed with qPCR (n per week = 1). 
 
 57 
 
 
Figure 41 - Abundance of Firmicutes, Lactobacilli and Bifidobacteria (16S rRNA gene copies/mL) in the mucosal 
microbiota during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO), in the 
proximal colon (PC) of the baby M-SHIME, inoculated with faecal material of baby 10, as assessed with qPCR (n per 
week = 1).     * : difference against control statistically significant (p-value < 0.05). 
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2. Discussion 
 
Base-Acid consumption 
The consumption of acid and base reflects the overall microbial activity 
throughout the SHIME experiment. Upon stabilization of the microbial community in the 
different reactors (starting from 2 weeks after inoculation), base-acid consumption is 
normally low. During treatment, bacteria may produce increased amounts of SCFAs and, 
as a consequence, the environment in the reactors will acidify, resulting in additional pH 
control by means of more administration of base to the respective reactors. As a result, 
the base-acid consumption will increase. By measuring the base-acid consumption 
throughout the experiment, the potential fermentation of GS, NMO and combinations 
thereof was estimated. 
Analysing Figure 25 we may conclude that all five treatments were well fermented 
as they resulted in an immediate increase of base-acid consumption at the start of the 
treatment. When calculating the average values for the control and two treatment weeks 
(Figure 26), it followed that the increases during the 1st treatment week as compared to 
the control period were similar among the different treatments.  Further, the values were 
also stable between the 1st and 2nd treatment weeks. This acidification is likely attributed 
to increased levels of SCFA and/or lactate production. 
Despite the supplementation of only 3.2 g/L (~1.26 g/day), the increases in base 
versus acid consumption thus confirms that GS and NMO are well fermented, with 
metabolic changes in the PCs. 
 
SCFAs 
As a first remark, as it should, during the control period the SCFAs levels were 
very stable within (on average 95.6% similar between consecutive time points in control 
period) and reproducible between each of the 5 SHIME units (on average 93.9% similar 
between the five different units). 
Secondly, the production of butyrate by the microbiota was the first sign for the 
presence of Bifidobacteria due to the process of cross-feeding (as explained in previous 
chapters).  
Finally, these graphs reveal that, despite the relatively low dose of 
supplementation (3.2 g/L), GS, NMO and combinations thereof were strongly fermented 
resulting in enhanced SCFA levels. These increases are relevant since prebiotic properties 
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of a product may be evaluated by the increase of propionate and/or butyrate. 
Further, acetate can exert antimicrobial effects against pathogens and is therefore also 
considered as a beneficial microbial metabolite. 
In conclusion, we may conclude that, because GS, NMO and combinations thereof 
increased the levels of all health-related SCFA (especially acetate, butyrate and only to 
minor extent propionate) in the proximal colons, they might thus result in distinct health 
benefits. 
 
Lactate 
As referred in the literature review, the human intestine harbours both lactate-
producing and lactate-utilizing bacteria. When produced by lactic acid bacteria, lactate 
decreases the pH of the environment. Especially at low pH values, lactate can exert strong 
antimicrobial effects against pathogens as it becomes protonated. This protonated lactic 
acid can penetrate microbial cells after which it dissociates and releases protons within 
the cell, resulting in acidification and microbial cell death. Another beneficial effect of 
lactate results from its conversion to butyrate by specific lactate-utilizing butyrate-
producing microorganisms such as Anaerostipes caccae, Anaerostipes hadrus or 
Eubacterium hallii. All this justifies the analysis of this metabolite. 
Relatively to Figure 32, the peaks in lactate production depended on the exact 
GS/NMO mixture that was supplemented: 
 Peak on day 1 after treatment for 90 GS/10 NMO (T1) 
 Peak on day 3 after the start of the treatment with 75 GS/25 NMO and 50 
GS/50 NMO (T2) 
 No peak for 100 GS and 100 NMO. As a remark, there might also have 
been peaks in lactate production for 100 GS and 100 NMO but they might 
have occurred in between two sampling points. 
As different microbial species thus produce and convert lactate, an increase of 
lactate concentration can both be the result of an increased production as well as a 
decreased conversion.  
Interestingly, the time point at which the peak in lactate again decreased to normal 
levels (T2 for 90/10 and T3 for 75/25 and 50/50), corresponded with increased levels of 
butyrate (Figure 27). This reveals the cross-feeding of lactate to butyrate by Clostridium 
cluster IV or XIVa species. The fact that a peak in lactate levels appeared reveals that 
upon GS/NMO administration, the lactate production likely increased (by e.g. 
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Lactobacilli or Bifidobacteria), while it took several days for the butyrate producing 
species to adapt to these increased lactate levels in order to enhance the lactate 
consumption.  
If that’s the case, this increased conversion of lactate to butyrate would be 
particularly interesting given the anti-inflammatory and anti-carcinogenic effects that are 
attributed to butyrate. 
 
Ammonium and branched SCFAs 
Both the production of ammonium (NH4
+) and branched SCFAs (b-SCFA = sum 
of isobutyrate, isovalerate and isocaproate) are the result of protein degradation and 
reflective for the proteolytic activity of the gut microbiota. As the latter has been 
associated with direct and indirect detrimental health effects (e.g. colon carcinogenesis), 
a reduction in ammonium/b-SCFA production is considered as beneficial. 
Despite the very low dose of supplementation (3.2 g/L ~1.26g/day), the 
50GS/50NMO mixture thus significantly decreased the levels of NH4
+, while also not 
resulting in a peak of b-SCFA.  
 
Qualitative analysis of the Bifidobacterium community 
composition (DGGE) 
The first observation concerning both luminal and mucosal DGGE pictures, 
relates do the control lanes (Figures 37 and 39). It is clear that the same enhanced band, 
referring to B. adolescentis, appears for every GS/NMO combination proving that, during 
control, every PC held the same bifidobacterial community and posterior changes were 
due to the different treatments applied.  
Secondly, as mentioned beforehand, when examining the DGGE pictures, two 
major conclusions can be withdrew: that GS stimulates B. longum and NMO increases 
the abundance of B. longum subsp. infantis. Further, there was a clear dose-response 
effect of increasing levels of NMO or GS on stimulation of the Bifidobacterium species 
that they selectively target. 
 Looking closely at the DGGE picture related to lumen (Figure 37), more 
particularly to 2nd treatment week (TR2) lanes (highlighted with blue squares), there is a 
gradual decrease of the intensity of the B. longum band. Simultaneously, the GS 
percentage decreases. This means that the abundance of B. longum is higher with 100GS 
(darkest band) than with 100NMO (lightest band).  
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In case of B. longum subsp. infantis, the darkest band showed up with 100NMO, while 
the lightest appeared with 100GS. For the two bacteria, this gradual increase/decrease in 
band intensity was also obvious even for the intermediate combinations of the test 
products, demonstrating a high degree of sensitivity of the bifidobacterial community to 
NMO (and GS).  
This abundance variance was alternatively exposed in a proportion graph (Figure 
38). Upon 100NMO, B. longum subsp. infantis increases drastically from 4% (control 
week) to 29%, and again to 37% (1st and 2nd treatment weeks, respectively). As well as 
the lumen, the mucus also showed the same pattern of variance for B. longum and B. 
longum subsp. infantis. The exact abundances of the latter for 100NMO were 2%, 15% 
and 17% at control and both treatment weeks, respectively. Once again, an accentuated 
increase of this specific Bifidobacterium is observable. This stimulation of specific 
Bifidobacteria promotes their growth over B. adolescentis and other Bifidobacterium sp.. 
In order to focus on the NMO-mediated increase of B. longum subsp. infantis, 
additional graphs focussing on this species were constructed and are presented in Figures 
41 and 42. It followed that from 25% NMO on, a decent stimulation of this species is 
observed upon a 2-week treatment period. 
 
 
 
Figure 42 - Abundance of B. longum subsp. infantis in the bifidobacterial DGGE profiles of the luminal microbiota 
during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO), in the proximal colon 
(PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n per week = 1). The phylogeny is based on the 
assumption that bands at the same height as during the previous project (2014) correspond with the same OTUs. 
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Quantitative analysis of the Bifidobacterium community 
composition (qPCR) 
Relevant ratios of different microbial groups were obtained during the control 
period, as compared to in vivo data. As an example, the graph below published by Fan et 
al. (2013), reports a microbiota composition of breast-fed infants at phylum level with 
levels of around 62 % Firmicutes, 21% Proteobacteria, 7% Actinobacteria and 10% others 
(including Bacteroidetes). Average levels obtained during the control period included 44 
(± 3%), 33 (± 4%), 5 (± 2%) and 17 (± 1%), respectively. 
 
 
Figure 44 - Microbiota composition of breast-fed infants at phylum level (Fan et al., 2013). 
  
Figure 43 - Abundance of B. longum subsp. infantis in the bifidobacterial DGGE profiles of the mucosal microbiota 
during the control and treatment period (100/0, 90/10, 75/25, 50/50 and 0/100 of GS/NMO), in the proximal colon 
(PC) of the baby M-SHIME, inoculated with faecal material of baby 10 (n per week = 1). The phylogeny is based on the 
assumption that bands at the same height as during the previous project (2014) correspond with the same OTUs. 
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During the 1st treatment week, all treatments tended to increase the Firmicutes 
(diverse phylum including many butyrate producers) and Bifidobacteria (containing 
health-related species) at the expense of Enterobacteria (containing disease-related 
microbes). 
While above mentioned beneficial community shifts were stable for GS during the 
2nd treatment week, NMO seemed to expand Enterobacteria levels in a dose-related way. 
This finding probably relates to recent studies showing that HMOs tend to increase 
Proteobacteria as this phylum contains members that are capable of cross-feeding on 
HMOs (Charbonneau et al., 2016; Frese et al., 2015). This means that these species are 
not necessarily primary degraders of NMO but rather benefit from degradation products 
of NMO that are produced by other microbes (like probably B. longum ssp. infantis). 
Given the fact that Enterobacteria also contain opportunistic pathogens, dosing 100% 
NMO might increase the risk of an intervention in vulnerable babies. On the other hand, 
Enterobacteria have also been shown to be essential for a correct priming of the immune 
system (Mai et al., 2011).  
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VI. CONCLUSION 
 
This study was focused on the response scenarios in terms of prebiotic effects, 
mainly on the assessment of the bifidogenic effects, of different mixtures of a 
conventional prebiotic (‘golden standard’) and a novel HMO in an infant’s microbiota.  
The first part of the project, a pre-screening, was performed in order to select the 
fittest faecal donor as this experiment provided valuable information on the inter-
individual differences among babies in response to NMO administration. While it is well 
known that the early-life microbiota composition can differ a lot among babies, it was 
interesting to observe that this also resulted in different response scenarios to NMO 
administration.  
Overall, 7 out of the 10 donors responded strongly to the NMO treatment resulting 
in an acidification of the medium as well as a bifidogenic effect, despite the fact that the 
NMO breakdown was likely mediated by different Bifidobacterium sp. in each of the 
different donors. NMO degradation can thus occur via several different ways, which is a 
pre-requisite for a good prebiotic as the infant gut microbiota is highly variable in terms 
of microbial colonization. 
Knowing that there are several response scenarios, it was decided to focus on the 
mechanism of action that was identified during a previous project and that was confirmed 
by the results of donor 10, in which NMO degradation was mediated by a specific species, 
specifically, B. longum subsp. infantis. 
The second part of the project was consisted on a baby M-SHIME, used to 
simulate the conditions of the GIT of babies, as described by De Boever et al. (2001). For 
this part of the study, the faecal sample of a single donor (donor 10) was used making this 
project still exploratory. 
As it should, during the control period, base-acid consumption, SCFAs, lactate, 
ammonium and microbiota composition were all very stable within and reproducible 
between each of the 5 PCs. This provided an excellent platform to benchmark the different 
mixtures of GS and NMO. 
Despite the supplementation of only 3.2 g/L (~ 1.26 g/day), the increases in base 
versus acid consumption confirmed that GS, NMO and combinations thereof were well 
fermented, with metabolic changes in the PCs. These changes included increased levels 
of all health-related SCFAs (especially acetate, butyrate and only to minor extent 
propionate). Shortly after the start of the treatment, a peak in lactate levels was observed, 
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likely due to enhanced production upon GS/NMO administration (by e.g. Lactobacilli or 
Bifidobacteria). The subsequent decrease in lactate levels corresponded with increased 
butyrate levels. This observation can be attributed to cross-feeding of lactate to butyrate 
by Clostridium cluster IV or XIVa species, which is particularly interesting given the anti-
inflammatory and anticarcinogenic effects of butyrate. A final metabolic result was that 
only minor decreases were observed on proteolytic markers. The treatment with 
significantly decreased levels of NH4
+ was the treatment with 50GS/50NMO. 
Regarding overall community changes, it followed that mucosal levels of 
Bifidobacteria, Lactobacilli and Firmicutes (diverse phylum including many butyrate 
producers), increased significantly upon dosing higher levels of NMO as compared to 
GS. With respect to luminal levels, it was found that during the 1st treatment week, all 
treatments tended to beneficially modify the baby microbiota with increases of Firmicutes 
and Bifidobacteria at the expense of Enterobacteria (containing disease-related microbes). 
During the 2nd week, it followed that NMO increased Enterobacteria levels in a dose-
related way. This finding probably relates to recent studies showing that HMOs tend to 
increase Proteobacteria as this phylum contains members (e.g. E. coli < Enterobacteria) 
that are capable of cross-feeding on HMOs. Given the fact that Enterobacteria also 
contain opportunistic pathogens, dosing would be recommended over 100NMO in order 
to avoid such a bloom in Enterobacteria.  
In conclusion, the optimal NMO dose might be the dose at which there is still a 
strong stimulation of B. longum ssp. infantis, and health-related SCFA, yet also being a 
dose that does not result in a major expansion of Enterobacteria. That being so, 
75GS/25NMO or 50GS/50NMO seem excellent candidates. 
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VIII. APPENDIX 
 
I 
 
Table 18 – Conditions and donors associated to each bottle. 
Condition 
 
Bottle 
Treatment Donor fresh faecal inoculum 
0 g/L 5 g/L 1 2 3 4 5 6 7 8 9 10 
1 (CTRL) X  X          
2 (TRT A)  X X          
3 (TRT B)  X X          
4 X   X         
5  X  X         
6  X  X         
7 X    X        
8  X   X        
9  X   X        
10 X     X       
11  X    X       
12  X    X       
13 X      X      
14  X     X      
15  X     X      
16 X       X     
17  X      X     
18  X      X     
19 X        X    
20  X       X    
21  X       X    
22 X         X   
23  X        X   
24  X        X   
25 X          X  
26  X         X  
27  X         X  
28 X           X 
29  X          X 
30  X          X 
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II 
 
Table 19 – SHIME nutritional medium (g/L) for an optimal simulation of the nutrient intake in babies. 
Nutritional medium 
components 
Stabilization 
and control 
Treatment 
100/0  90/10  75/25 50/50 0/100  
Pectin 1 1 1 1 1 1 
Mucin 4 4 4 4 4 4 
Starch 1 1 1 1 1 1 
Glucose 1 1 1 1 1 1 
Cellobiose 1 1 1 1 1 1 
Proteose peptone 2 2 2 2 2 2 
Pre-digested and pre-
absorbed infant 
formula: 
      
 Lactose 2.1 2.1 2.1 2.1 2.1 2.1 
 Casein 0.2 0.2 0.2 0.2 0.2 0.2 
 Whey proteins 
(lactalbumin) 
2.7 2.7 2.7 2.7 2.7 2.7 
Treatment:       
* NMO 0.1  2.88 2.4 1.6 3.2 
* GS 0.1 3.2 0.32 0.8 1.6  
TOTAL (g/L) 15.2 18.2 18.2 18.2 18.2 18.2 
 
 
